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ABSTRACT 
Commercial farming of barramundi or Asian seabass (Lates calcanfer) is a burgeoning 
industry in Australia and South East Asia. At present there are few serious bacterial 
infections, however disease caused by Vibrio harveyi infection is an on-going problem with 
the potential to become chronic as the industry expands. Therefore, the development of an 
effective vaccine against vibriosis was seen as a prudent strategy for the future success of 
barramundi production. This thesis reports on the development of appropriate reagents for in 
vitro monitoring of immune responses to a bacterin, and subsequent validation in laboratory 
trials where fish were immunised with a bacterin via various routes or, with 
lipopolysaccharide (LPS) via intraperitoneal (IP) injection. 
Barramundi immunoglobulin was isolated by affinity chromatography using either mannan-
binding protein (MBP) or Staphylococcal protein A (SpA) as capture ligands. Both isolation 
products were used to produce polyclonal antisera in rabbits, which were subsequently 
compared for specificity and titer. Two antisera were used to monitor anti-V. harveyi 
antibody activity in barramundi serum after primary and secondary immunisations with 
bacterin via the IP route. Elevated antibody levels after secondary immunisation indicated a 
memory response. 
The routes of bacterin administration were investigated in terms of antibody production and 
some non-specific immune parameters. It was found that barramundi respond systemically 
to bacterin delivered by IP injection, immersion (IMIM) and anal intubation (Al). The 
highest and most consistent response was in fish treated via IP followed by AT then IMM. 
This consistency of response from IP-treated fish carried over to bacterial inhibitory activity 
of serum where all demonstrated >50% inhibitory activity relative to non-immune controls. 
There was no significant enhancement of serum lysozyme activity nor head kidney 
macrophage phagocytic activity as a result of any immunisation procedure. 
Finally, the response of barramundi to IP immunisation with bacterin or lipopolysaccharide 
(LPS) extracted from the bacterium was compared to elucidate the role of the latter. There 
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were systemic antibody responses to both preparations with little difference noted in the 
magnitude of the response. However, bacterial inhibitory activity of serum was highest in 
the bacterin treament group. This may indicate that anti-LPS antibodies do not agglutinate to 
the same extent as anti-whole bacterial cell antibodies. 
In conclusion, systemic antibody and bacterial inhibitory activity after immunisations with 
the bacterin suggests that it may be an effective vaccine and oral administration is worth 
investigation. The protective role of LPS is unclear, though relatively lower bacterial 
inhibitory activity of anti-LPS antibodies suggests it may be less protective than anti-whole 
bacterial cell antibodies. 
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CHAPTER 1 
GENERAL INTRODUCTION 
As aquaculture expands and attempts to make up the worldwide deficit between supply from 
wild fisheries and demand for fish the risk of disease in these ventures also grows. The 
intensive nature of aquaculture imposes stresses which are regarded as being a significant 
contributor to the susceptibility of fish to diseases (Stoskopf, 1993). In addition, the high 
stocking densities employed allow for a greater risk of infectious contact between 
individuals and thereby precipitating epizootics. Good animal husbandry together with the 
use of disinfectants and therapeutants such as antibiotics have done much to lessen disease 
impact. However, they are no longer sufficient to adequately control disease problems in 
aquaculture. Moreover, the use of antibiotics and other chemicals has led to concerns over 
drug resistance and environmental contamination and may lead to restricted use of some 
chemicals. In any case therapeutants such as antibiotics are expensive, may require multiple 
doses and are generally applied only after fish show signs of disease (Horne and Ellis, 
1988). Therefore, it is prudent to continue investigations into prophylactic measures such as 
vaccination as a means of controlling disease. 
The exhibition of adaptive immunity by fish suggested that vaccination would be a feasible 
method of disease control. Although immunisation of fish was attempted in the 1940s (Duff, 
1942) the economic impetus to protect cultured fish stocks did not arise until the 1970s 
(Newman, 1993). Since then there has been much success with vaccines against bacterial 
pathogens. Fundamentally, the development of effective vaccines requires understanding of 
the immune system together with the nature of the antigens which may induce a protective 
response on exposure to fish. To that end much of the research in the field of fish 
immunology has focussed on defining and understanding fish immune systems in 
comparison to those of mammals. These tasks have been made easier by employing genetic 
and biochemical techniques which enable minute examination of the machinery and 
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processes involved. Thus, during the 1980s and 1990s, the research has broadly gone in two 
directions: furthering an understanding of fish immunity and, application of this knowledge 
to enhance protection from disease in cultured fish. Aside from knowledge useful in a 
- practical sense, the first direction provides, from a holistic perspective, fundamental data on 
the evolution of immune systems (Miller et al., 1998). The second encompasses 
characterisation of antigenic components of pathogens, ontogeny of immune system of fish, 
vaccine administration routes and formulation and trials of prototype vaccines. The 
magnitude of research performed and reported and the diversity of the species studied are 
virtual acknowledgement of fish vaccinology as a discipline in its own right (Ellis, 1999a). 
1.1 IMMUNITY IN TELEOST FISH 
The immune system of teleost fish is fundamentally similar to that of higher vertebrates and, 
therefore, fish are generally well-equipped to protect themselves against pathogenic 
organisms. Teleosts possess both humoral and cell-mediated immunity which are further 
classified as specific and non-specific. Vaccination allows a host to develop resistance 
against a disease by stimulating specific and non-specific immunity and considerable 
interaction between both immune arms occurs in an effective response. Numerous recent 
reviews and texts have more than adequately dealt with aspects of piscine immune 
mechanisms (e.g. Sakai, 1992; Kaattari, 1994; van Muiswinkel, 1995; Iwama and Nakanishi, 
1996; Miller et al., 1998; Partula, 1999), therefore this introduction will concentrate more on 
the overview and the pertinence of work in the field of fish vaccinology. 
Vaccination can activate acquired immunity in a host to specific antigens and such immunity 
is characterised by specificity and memory (Warr, 1996). Fish display cellular and humoral 
immunity which have these characteristics (van Muiswinkel, 1995) and are therefore 
amenable to vaccination. Many of the existing immune components in fish are similar to 
those in mammals, for example equivalents of T and B lymphocytes which are the effector 
cells of acquired immunity and antigen-presenting or accessory cells which include 
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monocyte/macrophages (Vallejo et al., 1992.). The B cells, with surface immunoglobulin, 
(sIg+) can be distinguished from lymphoid cells with no surface Ig (sIg" i.e. T cells) by 
monoclonal antibodies (mAbs) (Miller et al., 1998). T cells can also be distinguished using 
mAbs to T cell specific markers in fish species such as carp, Cyprinus carpio, (Rombout et 
al., 1997; Rombout et al., 1998) European seabass, Dicentrarchus labrax, (Scapigliati et al., 
1995) and channel catfish, Ictalurus punctatus (Passer et al., 1996). In terms of mitogenic 
responses, it has been demonstrated that channel catfish have T helper cells, B cells and 
accessory cells similar to those of mammals (Sizemore et al., 1984; Miller et al., 1985). This 
was shown using known T and B cell mitogens such as concanavalin A (Con A) and 
lipopolysaccharide (LPS) respectively. Observations of sIg + response to LPS but not Con A 
suggested sIg+ of catfish to be B cells and sIg -cells were thought to be T cells based on 
mitogenic responses to Con A, these cells also responded to LPS which is in contrast to 
mammalian T cells (Sizemore et al., 1984). Similarly in catfish, an in vitro antibody 
response to a thymus-dependent antigen in a sig.' lymphocyte population required the 
presence of sIg" lymphocytes and accessory cells whereas when a thymus-independent 
antigen was used only sIg + lymphocytes and accessory cells were required (Miller et al., 
1985). 
Notwithstanding the similarities, piscine immunity is often seen as simplistic compared to 
immunity in higher vertebrates. Aside from the phylogenetic position of fish relative to 
mammals, reasons for this perception are, in part, due to comparisons being made between 
two systems where only one has been extensively studied (Kaattari, 1998). Another reason 
relates to current knowledge of the differences between the acquired immune responses of 
teleosts and mammals. Immunological memory in fish is less complex than that in higher 
vertebrates (Newman, 1993), for example fish are thought not to possess physiologically 
distinct memory cells and an elevated secondary humoral response may be due to an 
increase in the antigen-specific B cell pool (Arkoosh and Kaattari, 1991). This is important 
as the concept of immunological memory is one basis for vaccination. The predominant 
class of teleost Ig is thought to be equivalent to mammalian IgM (Pilstrom and Bengten, 
1996). Even though isotypic variation is accepted in Ig of fish (Kaattari, 1994) isotype 
switching within a single B cell is yet to be conclusively demonstrated. Similarly, affinity 
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maturation, manifest as a logarithmic increase in antibody affinity, has not been observed 
(Arkoosh and Kaattari, 1991). Kaattari (1994) postulated that reasons for a lack of affinity 
maturation may be due to nature of the response. For example, T suppressor cells seem to 
exert a more intense control on antibody affinity than in mammals as evidenced in studies 
where T suppressor cells were removed via gentle radiation and subsequent increase in 
antibody activity observed (Kaattari et a/., 1986). A different theory for lack of affinity 
maturation in teleosts concerns the way in which it is assessed (Kaattari 1994). Commonly, 
measurement of affinity maturation is determined from individual binding sites on an Ig 
molecule however, as fish predominantly have tetrameric IgM then modest affinity increases 
at each binding site may be magnified logarithmically when the functional affinity of the 
whole molecule is assessed (Kaattari, 1994). This may indicate that fish immunity has 
evolved differently to that of mammals and that using mammalian criteria to define fish 
immunity may lead to erroneous interpretation (Kaattari, 1994). The tools required to 
properly elucidate fish immunity, such as monoclonal mAbs to T cell markers are currently 
limited (Rombout et al., 1998). However, at present this is a very active area of research as it 
has profound implications in discerning the ontogeny of T cells and subsequent development 
of an active inducible immune response. 
A consistent theme in some research into fish immune systems through the 1980s and 1990s 
was identification and elucidation of mucosal immunity. The importance to fish of this 
apparently autonomous immune compartment is highlighted by the fact the skin provides 
another mucosal barrier in addition to the gill and alimentary tract. A degree of autonomy of 
the mucosal immune system is indicated by observations in mammals that mucosal and 
systemic immunity can be stimulated if immunisation occurs by a mucosal route, however 
systemic immunisation does not usually induce mucosal immunity (McGhee et al., 1992; 
Hathaway and Kraehenbuhl, 2000). After antigen delivery to lymphoid tissue in mucosal 
inductive sites (i.e. gastrointestinal, respiratory and genitourinary tracts) and presentation to 
lymphocytes, stimulated T and B cells are transported via lymphatic, then systemic, 
circulation to distant mucosal sites where B cells are selectively retained (McGhee et al., 
1992). Clarification of this common mucosal immune system will aid in vaccine design and 
delivery to the mucosal sites with the aim to induce protection at the site of infection 
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(McGhee et al., 1992). This is equally important in fish as most horizontally transmitted 
pathogens enter fish via the mucosal barriers (Evelyn, 1996). In examining mucosal 
immunity in fish the research initially looked at secretory Ig and antibody activity was 
described in fish mucus during the 1970s (e.g. DiConza and Halliday, 1971). Some 
examples of descriptions and elicitation of Ig in fish appear in Table 1.1. The elicitation of 
antibody in skin mucus with little or no concomitant serum antibody after oral antigen 
delivery (Fletcher and White, 1973; Kawai et al., 1981; Rombout et al., 1993a) indicated a 
degree of autonomy of mucosal immunity. Further, Lobb (1987) elicited antigen-specific 
antibody in the mucus of channel catfish after immersion in dinitrophenylated horse serum 
albumin but found no increase in post-immersion antibody activity in the serum. Although 
Wong et al. (1992) found significant mucus and serum antibody levels in coho salmon after 
oral administration of an enterically coated V. anguillarum vaccine, Cain et al. (2000) noted 
an important difference. These authors found antibody in the mucus and serum of rainbow 
trout using a hapten-carrier antigen delivered by IP injection and anal intubation but noted 
that peak mucus response occurred 2 weeks prior to the peak serum response. This may 
indicate independent antibody production within mucosal and systemic compartments (Cain 
et al., 2000). 
Lobb and Clem (1981) suggested that Ig present in cutaneous mucus and bile of channel 
catfish was locally synthesised after demonstrating that Ig was not transudated nor actively 
transported from the serum. Rombout et al. (1993a) demonstrated antigenic differences 
between the heavy chains of mucus and serum Ig in carp using mAbs. In fish the mucosal 
inductive sites are those where lymphoid cells, but not distinct tissue, have been shown to be 
present. Such sites include the intestine (Rombout et al., 1986) and to a lesser extent 
leucocytes are also present in the skin and gills (van Muiswinkel, 1995). The mechanisms 
required for antigen uptake and transport across the epithelium to these cells are all present 
in the intestine (Rombout et al., 1993b) and apparently the skin and gills. Moore et al. 
(1998) quantified particulate antigen in various tissues of rainbow trout after immersion in a 
suspension of polystyrene microspheres linked to bovine serum albumin (BSA). These 
authors observed persistence of the particles for up to 24 days in epithelial cells of the skin 
and phagocytes underlying the epithelia of both the skin and gills and relatively small 
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numbers of particles in the kidney and spleen. It was suggested that retention of antigen at 
the site of uptake was consistent with the role of local immune responses and protection 
after immersion immunisation with little or no concomitant systemic antibody production 
(Moore et al., 1998). Further evidence of a distinction in mucosal and systemic immunity is 
the apparent difference in the kinetics of antibody-secreting cells (ASC) in both 
compartments (Kaattari and Piganelli, 1996). Davidson et al. (1993) found ASC in both the 
head kidney and intestinal mucosa of rainbow trout after intraperitoneal (IP) injection and 
oral intubation with an Aeromonas salmonicida bacterin, although differences were noted in 
each depending on the immunisation route. Antigen-specific ASC appeared in the head 
kidney 2 weeks after IP injection but were not noted until 7 weeks later in the intestinal 
mucosa (Davidson et al. 1993). Conversely, ASC appeared simultaneously in both tissues 
after oral intubation with the bacterin (Davidson et al. 1993). 
Much of the evidence suggests that, as in mammals, fish possess a mucosal immune system 
that can, to some extent, act independently of systemic immunity and work continues in this 
area. Therefore, as in mammalian vaccinology, full elucidation of the mucosal immune 
system will mean that researchers will be in a much better position to devise strategies that 
optimise enhancement of immunity. 
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Table 1.1 Examples of existence and detection of mucosal immunoglobulin in fish 
Species Mucus source Antigen Administration route Detection method 
Catfish (Tachysurus Skin Salmonella enteritis Intraperitoneal (IP) Bacterial agglutination 1 
australis) bacterin injection 
Gar (Lepisosteus 
platyrhincus) 
Skin Sheep red blood cells IP injection Haemagglutination 2 
Plaice (P. platessa) Skin Vibrio anguillarum 
bacterin 
IP injection Haemagglutination 3 
Rainbow trout Skin V. anguillarum bacterin IP injection Bacterial agglutination 4 
(Oncorhynchus mykiss) 
Channel catfish 
(ktalurus punctatus) 
Skin Salmonella paratyphi 
bacterin 
IP injection Bacterial agglutination 5 
Table 1.1 Continued 
Species 	 Mucus source 	 Antigen 	 Administration route 	Detection method 
Rainbow trout (0. 	Skin 	 Sheep red blood cells 
	IP injection 	 Haemagglutination 6 
mykiss) 
Tilapia (Oreochromis 	Skin 	 Human gamma globulin IP injection 
	 Enzyme-linked 
mossambicus) 
	
(HGG) 
	
immunosorbent assay 
(ELISA) 7 
Channel catfish (I. 	Skin/Intestine 	 Edwardsiella ictaluri 	IP injection/Anal 	ELISA 8 
punctatus) 
	
bacterin/outer membrane 
proteins 
Channel catfish (I. 	Skin 	 Dinitrophenylated horse Immersion 	 Haemagglutination 9 
punctatus) 	 serum albumin 
Plaice (P. platessa) 	Skin 	 V anguillarum bacterin 	 Haemagglutination 3 
00 
Table 1.1 Continued 
Species Mucus source Antigen Administration route Detection method 
Ayu (Plecoglossus 
altivelis) 
Skin V. anguillarum bacterin Oral Bacterial agglutination ' 
Carp (Cyprinus carpio) Skin Soluble ferritin Oral ELISA 11 
Coho salmon 
(Oncorhynchus kisutch) 
Skin V .anguillarum 
lyophilised and enteric 
coated 
Oral ELISA 12 
Tilapia (0. 
mossambicus) 
Skin HGG in micelles Oral/Anal ELISA 7 
Carp (C. catpio) Intestine V. anguillarum bacterin Anal ELISA " 
VD 
Table 1.1 Continued 
Species 	 Mucus source 	 Antigen 	 Administration route 	Detection method 
Rainbow trout (0. 	Gill 	 Flavobacterium 	IP injection/Immersion 	ELISA 
mykiss) 	 branchiophilum bacterin 
Turbot (Scophthalmus 	Skin/Intestine 	 LPS from Cytophaga- 	IP injection 
maximus) 	 like bacterium 
LPS coated latex 	Oral/Immersion 
Rainbow trout (0. 	Skin 	 Fluorescein 	 IP injection/Anal 
mykiss) 	 isothiocyanate 
conjugated to keyhole 
limpet haemocyanin 
Haemagglutination 
ELISA 
Rainbow trout (0. 	 Encapsulated HGG 	Oral 	 ELISA 
mykiss) 
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1.2 VACCINATION AGAINST BACTERIAL PATHOGENS 
The simple approach of inactivating a culture of a pathogen and administering it to a 
potential host has been an effective vaccine strategy in many situations. Primary examples 
include the first vaccines developed for vibriosis and yersiniosis/enteric redmouth caused by 
Vibrio anguillarum and Yersinia ruckeri infections respectively. Mass immunisation via 
immersion is highly effective for yersiniosis (Ellis, 1988a). Similarly, initial vaccines 
developed against V. anguillarum also displayed good protection (e.g. Antipa and Amend, 
1977; Gould et al., 1978) and paved the way for subsequent use of inactivated cultures as 
vaccines. In general these inactivated cultures or bacterins comprise a crude mixture of 
whole cells, cell debris and intracelluar and extracellular products some of which are 
immunogenic and provide protection. In fact most of the currently available commercial 
vaccines against bacterial pathogens are bacterins or their components albeit in some cases 
delivered with adjuvants (Newman, 1993). This vaccination strategy has not worked in all 
cases, a striking example was the failure for a number of years to produce a consistently 
effective vaccine against furunculosis, a disease caused by infection with Aeromonas 
salmonicida. The complex relationship between host and pathogen, expression of different 
substances when residing in the host or a culture medium and, the ability of the organism to 
circumvent some host defence mechanisms all conspired to make vaccine development 
difficult. Such an example underlines the need for a more systematic approach to vaccine 
design where immunogenic determinants are identified in particular those associated with 
virulence. These investigations also have the potential to uncover determinants that may 
provide cross-protection within strains of a pathogen, for example it is desirable for an 
effective furunculosis vaccine to confer protection against disease caused by atypical A. 
salmonicida strains (Hastings, 1988). 
Different approaches are also required when confronted with a pathogen such as 
Renibacterium salmoninarum, the causative agent of bacterial kidney disease in salmonids. 
This organism is both an extracellular and intracellular pathogen, residing in monocytes and 
macrophages (Bruno, 1986) where it auto-agglutinates and is possibly protected against 
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enzymatic degradation (Bruno, 1988). R. salmoninarum is fastidious in its growth 
requirements and extremely long generation times make isolation from tissues and then 
culture very time consuming (Newman, 1993). These characteristics pose problems with 
methods used for testing efficacy of vaccines. The rapid development of molecular 
biological techniques aiding in antigen identification and subsequent production of subunit 
and DNA vaccines will help overcome some of the problems associated with vaccine 
development for the more troublesome pathogens. There are now several commercially 
available vaccines used against bacterial pathogens in finfish culture throughout the world 
and these together with the vaccine development status of other bacterial pathogens are 
detailed in Table 1.2. 
The types of vaccines used and under development against bacterial pathogens include 
bacterins, incorporating monovalent and polyvalent preparations, and live attenuated 
organisms. The use of polyvalent vaccines seem to have two advantages: protection can be 
conferred against multiple pathogens and there are sometimes synergistic effects. For 
example, commercial vaccines are available that are made up of V. anguillarum, V. 
salmonicida and A. salmonicida antigens with adjuvant which are routinely used in Norway 
(Press and Lillehaug, 1995; Hoel et al., 1998). A synergistic effect with this polyvalent 
vaccine was noted in experiments where enhancement of protection against furunculosis was 
found relative to groups given A. salmonicida antigens only (Midtlyng et al., 1996). Hoel et 
al. (1997) subsequently proposed that the V. salmonicida component was probably 
responsible for the enhancement and effectively acted as an adjuvant. Concerns about 
antigenic competition in polyvalent vaccines and possible suppressive effects were partially 
dispelled when Amend and Johnson (1984) found no antigenic competition in salmonids 
when administered various combinations of V. anguillarum, Y. ruckeri, A. salmonicida and 
R. salmoninarum bacterins. 
The potential of live vaccines for cultured fish has been recognised and appears to offer 
distinct benefits. Live vaccines can activate responses similar to those seen during natural 
infection, particularly cell-mediated responses (Marsden et al., 1996a) required for 
elimination of intracellular pathogens (Kaufmann, 1995) and, they may express antigenic 
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substances in vivo that may be lacking during in vitro culture as in bacterin manufacture 
(Brown et al., 1993). Another advantage of vaccination with live attenuated bacteria is that it 
is effectively an infection and therefore relatively lower doses could be used to initiate the 
infection and then, if bacterial cells are shed, could facilitate dissemination throughout a 
population (Gudding et al., 1999). Genetically attenuated strains of A. salmonicida have 
been proposed as vaccines against furunculosis (Vaughan et al., 1993; Thornton et al., 1994; 
Marsden et al., 1996a; Marsden et al., 1996b) to exploit these advantages, and experimental 
results have been promising. The major disadvantages include the risk of a return to 
virulence, and adverse perceptions of using genetically modified organisms on fish farms. 
These factors are likely to impede commercial licensing. 
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Table 1.2 Bacterial diseases in finfish and current status regarding vaccine development 
Disease- 
Species affected 
Causative 
organism 
Existing/proposed 
vaccine type 
Administration 
method 
Development status 
Vibriosis- 
farmed marine fish 
Vibrio anguillarum Bacterin Injection/Immersion Commercially available 1,2 
Vibriosis- 
farmed marine fish 
Vibrio ordalii Bacterin Injection/Immersion Commercially available 1,2 
Cold 	water 	vibriosis Vibrio salmonicida Bacterin Injection/Immersion Commercially available 14 
Hitra disease-
salmonids 
Winter ulcer disease- 	Vibrio viscosus 	Polyvalent 	Injection 	 Not commercially available, 
farmed Atlantic 	 Bacterin with experimental results good 2 '3 
salmon 	 adjuvant 
Table 1.2 Continued 
Disease - Causative Existing/proposed Administration 
species affected organism vaccine type method 
Yersiniosis/Enteric red 
mouth- 
salmonids 
Yersinia ruckeri Bacterin Immersion 
Furunculosis- Aeromonas Bacterin Injection/Immersion 
salmonids salmonicida 	subsp. 
salmonicida 
with adjuvant 
Ulcer disease-
numerous farmed fish 
A. salmonicida 
atypical strains 
Bacterin Injection 
Aeromonad Aeromonas Bacterin or Injection/Oral 
septicemia- 
numerous farmed fish 
hydrophila attenuated live cells 
Commercially available,' research 
on-going 4 
Not commercially available, research 
on-going 5'6 
Development status 
Commercially available 14 
Commercially available, 1 '2 research 
on-going 
P-ci■ 
Table 1.2 Continued 
Disease- 	 Causative 	 Existing/proposed 
	
Administration 	Development status 
Species affected 	organism vaccine type 	method 
Pasteurellosis/ 
	
Photobacterium 	Bacterin or antigenic Injection/Immersion 	Not commercially available, research 
Pseudotuberculosis- 	damsela subsp. 	components 	 on-going 2,7 
farmed marine fish 	piscida 
Edwardsiellosis- 	Edwardsiella tarda 	Bacterin or outer 	Injection 	 Not commercially available, research 
eels, marine fish membrane protein on-going 8 
Enteric septicemia-
channel catfish 
Bacterial kidney 
disease- 
salmonids 
Edwardsiella 
ictaluri 
Renibacterium 
salmoninarum 
live attenuated cells 	Immersion 
Modified bacterin 	Injection/Oral 
Not commercially available, 
experimental results good, research 
on-going 9 
Not commercially available, 
experimental results good, research 
on-going " 
Cutaneous erosion, 	Flexibacter 	spp Bacterin 	 Injection 	 Not commercially available, research 
skin/tail rot- 	 Cytophaga spp 	(F. columnaris) 	 on-going" 
numerous farmed fish 
Table 1.2 Continued 
Disease- Causative Existing/proposed Administration 
Species affected organism vaccine type method 
Rickettsial septicemia- 
salmonids 
Piscirickettsia 
salmonis 
Bacterin Injection 
Streptococcosis-
numerous farmed fish 
Streptococcus iniae Bacterin Injection 
Lactococcosis- 
rainbow trout, yellow 
tail 
Lactococcus garviae Bacterin Injection 
Development status 
Not commercially available, research 
on-going 12,13 
Not commercially available, 
experimental results good, research 
on-going 14,15 
Not commercially available, research 
on-going 16 
1.Press and Lillehaug, 1995 
2.Haenen, 2000 
Gregor and Goodrich, 1999 
Wiklund and Dalsgaard, 1998 
• Leung et al., 1997 
6. Azad et al., 1999 
7. dos Santos, 2000 
8- Tu and Kawai, 1999 
Wise et al., 2000 
Piganelli et a/.,1999 
Bader et al., 1997 
12. Smith et al., 1995 
Almendras and Fuentealba, 1997 
14.Eldar et al., 1997 
15.Klesius et al., 2000 
Akhlaghi et al., 1996 
1.3 BARRAMUNDI (Lates calcarifer) AQUACULTURE 
Lutes calcarifer is a euryhaline species which is a member of the subfamily Latinae from the 
family Centropomidae (Nelson, 1994). This species is widely distributed throughout the 
Indo-West Pacific region (Grey, 1987) where it is variously known as seabass or Asian 
seabass or, in Australia and Papua New Guinea, barramundi (Rimmer and Russell, 1998). 
The fish is protandrous, catadromous species that is particularly suited to culture. It is 
extremely fast-growing and very tolerant of relatively poor environmental conditions. 
Moreover, in Australia, it has been traditionally a popular recreational species renowned for 
its angling and flesh qualities, the latter attribute ensuring a robust market for the farmed 
product. Chief producers of barramundi worldwide are Indonesia, Malaysia, Philippines and 
Thailand (Grey, 1987). In Australia, barramundi aquaculture is a burgeoning industry as 
evident by the growth in production from 219t in 1993 (FAO, 1995) to approximately 633t 
in 1997/98 (O'Sullivan and Roberts, 2000). 
Barramudi are cultured in either freshwater, brackishwater or seawater, though their 
catadromous nature means that broodstock require seawater to facilitate final gonadal 
maturation (Rimmer and Russell, 1998). The larvae are also reared in seawater but at the 
juvenile stage they may be on-grown in brackishwater or freshwater. 
In both nursery and grow-out phases cultured barramundi are prone to diseases from a range 
of pathogenic organisms. Although parasitic, fungal and viral infections do occur these are 
less common than bacterial diseases (Anderson and Norton, 1991). Parasites including 
ciliated protozoans, trematodes and crustaceans have all been reported (Choncheunchob et 
al., 1987; Glazebrook and Campbell, 1987; Humphrey and Langdon, 1987) but do not 
appear to be major concerns. Periodic mass mortalities at the larval stage early in the 
development of the industry have variously been attributed to dietary deficiencies (Rodgers 
and Barlow, 1987) and to a viral encephalopathy caused by a picorna-like virus 
(Glazenbrook, 1990). The virus has since been shown to be antigenically similar to 
nodavirus (Munday et al., 1994) and in fact was identified as belonging to the family 
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Nodaviridae (Comps et al., 1994). However, the institution of improved hatchery techniques 
has been very successful in controlling outbreaks of this disease (Munday et al., 1994). Most 
commonly, mortalities in farmed barramundi are caused by bacterial infections (Anderson 
and Norton, 1991) such as those by Streptococcus iniae (Bromage et al., 1999). In addition, 
diseases caused by bacteria of the genera Vibrio, Aeromonas, Pasteurella, Streptococcus and 
Flexibacter/Cytophaga have all been reported (Rimmer and Russell, 1998). Vibriosis has 
been associated with poor environmental and nutritional conditions in some instances 
(Subasinghe and Shariff, 1992) suggesting that improved husbandry techniques may aid in 
control of this disease. In Australia, there is an on-going disease problem with vibriosis 
caused by infection with Vibrio harveyi (Rachel Webb, pers comm) which occurs during the 
seawater and bracicishwater part of the culture period. Though there have been no serious 
losses due to this disease in Australia, the potential for vibriosis to become a chronic 
problem exists, particularly if the industry intensifies as the growth in production figures 
suggest. Therefore, the development of an effective vaccine against vibriosis caused by V. 
harveyi infection was seen as a prudent strategy for the future success of barramundi 
production, particularly since antibiotic resistant isolates have already been described in 
penaeid prawn culture (Karunasagar, 1994). 
1.4 THE PATHOGEN Vibrio harveyi 
Members of the Vibrio genus of bacteria have been described as the scourge of marine fish 
and shellfish culture (Austin and Austin, 1993) with the severity of the disease increasing 
with the expansion of mariculture (Smith, 1988). Vibriosis has been problematic wherever 
finfish culture occurs in the world. Fortunately, diseases caused by V. anguillarum, V. 
ordalii and V. salomonicida have been shown to be amenable to control by vaccination 
(Newman, 1993). 
V. harveyi is a common water-borne bacterium known to cause disease in a wide range of 
marine animals (Zhang and Austin, 2000). The bacterium is a pathogen of penaeid shrimp 
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(Kanmasagar et al., 1994; Alvarez et al., 1998; Robertson et al., 1998), has been implicated 
in diseases of rock lobster (Diggles et al., 2000) and in a range of fish species including the 
common snook, Centropomus undecimalis, (Kraxberger-Beatty et al., 1990), dentex, Dentex 
dentex, (Company et al., 1999), rainbow trout, Oncorhynchus mykiss, and Atlantic salmon, 
Salmo salar, (Zhang and Austin, 2000). The bacterium is possibly implicated in disease in 
an even wider range of fish species given that another fish pathogen, Vibrio carchariae, is 
now described as a junior synonym of V. harveyi (Pederson et al., 1998). The pathogenicity 
mechanisms of the bacterium have not been fully elucidated, though are thought to involve 
extracellular products (Austin and Austin, 1993). There is a relationship between 
siderophore production and virulence in fish (Owens et al., 1996), and Harris and Owens 
(1999) characterised protein exotoxins from strains pathogenic to penaeid prawns that were 
lethal to prawns and mice. However, this may be further complicated by the role of 
bacteriophages in the toxicity of V. harveyi. Ruangpan et al., (1999) reported mediation in 
toxicity of V. harveyi to penaeid prawns via transfer of genes controlling toxin production. 
As with disease caused by other members of the genus, vibriosis is systemic with fish 
displaying haemorrhagic lesions, necrosis in the liver (Company et al., 1999) and 
occasionally exopthalmia and corneal opacity (Kraxberger-Beatty et al., 1990; Company et 
al., 1999). In Queensland, vibriosis is usually an acute disease affecting fingerling 
barramundi reared in seacages, with heavy infections resulting in fatalities within 24-48 h 
(Annette Thomas, pers comm). 
15 OUTLINE AND AIMS OF THIS THESIS 
A starting point in the development of a vaccine against vibriosis caused by V. harveyi in 
barramundi was to examine the immune response of the fish to a bacterin. This was seen as 
reasonable given the success of inactivated cell cultures or bacterins as vaccines for 
protection against some forms of vibriosis. An important consideration is the ease and 
economy of vaccine production and it needs to be established whether a bacterin can be an 
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effective vaccine. Therefore the overall aim of this study was to examine the humoral 
immune response of barramundi to a bacterin prepared from V. harveyi culture as a potential 
vaccine candidate. The work carried out for this thesis forms one part of a combined effort 
within the Cooperative Research Centre for Aquaculture (Aquaculture CRC Ltd., Australia) 
and field trials evaluating potential vaccines are to be performed by others participants. The 
findings from this work should form the basis for future work, not only into in vivo 
assessment of prospective vaccines for vibrioisis, but also into more detailed analyses of the 
barramundi immune system. 
Firstly, since no anti- barramundi Ig antisera were commercially available, the investigation 
required the development of specific reagents capable of measuring the specific humoral or 
antibody response in barramundi (Chapter 2). Chapter 3 is a general materials and methods 
section comprising development of appropriate assays to quantify the immune response, 
preparation techniques of the bacterium as a bacterin and fish husbandry. The first 
experiment (Chapter 4) attempted to appraise the specific antibody response in the serum 
and mucus (skin and gut) of barramundi to a bacterin administered with an adjuvant via 
intraperitoneal (IP) injection or immersion (IMM). As the bacterin had not been 
administered to barramundi before and there is little or no published information on 
barramundi humoral responses an adjuvant was used for the injection to be sure of a 
detectable response. A degree of duplication was unavoidable for the second experiment 
(Chapter 5) as a different strain of the bacterium had been identified at this time as being 
more pathogenic and as a candidate for commercial vaccine and was subsequently used in 
the trial. Having established the ability of the bacterin to elicit a systemic antibody response 
by IP injection, with adjuvant, and IMM the second experiment attempted to confirm 
observation of an apparent anamnestic response without adjuvant. This experiment also 
compared bacterin administration techniques of IP injection, IMM and anal intubation (AI) 
as simulation of oral antigen delivery to gut-associated lymphoid tissue. With a view to the 
possibility of developing broadly cross-protective vaccines, the final experiment (Chapter 6) 
attempted to elucidate the immunogenicity of lipopolysaccharide (LPS) extracted from V. 
harveyi. Lipopolysaccharide has been postulated as the protective antigen in other Vibrio 
vaccines and may have the potential to be a cross-protective antigen. Additionally, LPS may 
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be an appropriate candidate for oral administration as the polymer may be resistant to the 
enzymatic degradation in the gut. The final discussion (Chapter 7) underlines the major 
findings and points out the applicability of the results to the development of an effective 
against vibriosis for barramundi. 
23 
CHAPTER 2 
REAGENT DEVELOPMENT FOR AN ELISA TO DETECT SPECIFIC ANTIBODY 
IN VACCINATED AND NON-VACCINATED BARRAMUNDI (Lates calcarifer) 
2.1 INTRODUCTION 
Inherent in research efforts in the field of fish vaccinology is the need to evaluate the 
effectiveness of prospective vaccines in terms of protection and their ability to stimulate 
specific immune responses (Hastings, 1988). Experimentally this can be done by pathogen 
challenge models and the monitoring of the adaptive humoral response. The latter is 
important for a number of reasons. For example: to determine whether there is a correlation 
between antibody levels and protection, for a more complete understanding of the immune 
mechanisms enhanced and, to monitor immunogenicity and the protective nature of 
individual antigens. If there is a positive correlation between protection and antibody and the 
antibodies have been demonstrated to be protective, then monitoring antibody production 
will give an indication that the fish have responded to vaccination and are protected against 
the disease. Measurement of antibodies specific to vaccine antigens can be used as a means 
of quality control for specific batches of a vaccine. An essential starting point to monitor 
antibody production is the development of an ELISA to measure antigen-specific antibody 
activity. 
Antisera able to detect barramundi immunoglobulin (Ig) are required to develop this ELISA. 
Although mAbs are often used as secondary antibodies in such ELISAs and there are now 
several available that recognise Ig from various teleosts (Scapigliatti, 1996), polyclonal 
antibodies, if of sufficient specificity, are commonly used. As neither monoclonal nor 
polyclonal antibodies to barramundi Ig are readily available the first part of this study 
reports on the isolation of barramundi Ig and the subsequent production of polyclona1 
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antisera against the Ig. In doing so purification of barramundi Ig by affinity chromatography 
using Staphylococcal protein A (SpA) or mannan-binding protein (MBP) as capture ligands 
are compared as are the subsequent antisera that result from the immunisation of rabbits 
with both whole Ig molecules and heavy (H) chain or light (L) chain polypeptide 
components. 
2.2 MATERIALS AND METHODS 
2.2.1 Purification of barramundi immunoglobulin 
Barramundi serum was procured from experimental fish held at the Queensland Department 
of Primary Industry in Townsville and The School of Aquaculture, University of Tasmania, 
Launceston. Two affinity chromatography methods were used to partially purify barramundi 
Ig which was then used to produce antibodies in rabbits. Capture ligands used for each 
method were MBP procured from rabbits and SpA. 
MBP-purified Ig was obtained by using a mannan-binding protein affinity chromatography 
kit (ImmunoPure® IgM Purification Kit, Pierce, IL, USA) with a 5 mL bed volume. Briefly, 
serum was dialysed against 4 x 1 L changes of sample buffer (10 mM tris, 1.25 M NaC1, 
0.02% NaN3, pH 7.4) at 4°C. After dialysis the serum was diluted 1:1 with a binding buffer 
(10 mM tris, 1.25 M NaC1, 20 mM CaC1 2, 0.02% NaN3 , pH 7.4). Prior to the introduction of 
1 mL of the diluted sample, the affinity column was washed at room temperature with 5 mL 
of elution buffer (10 mM tris, 1.25 M NaC1, 0.02% NaN 3, 2 mM EDTA, pH 7.4), then 
equilibrated at 4°C with 20 mL of binding buffer. The serum was incubated on the column 
for 30 min after which free protein was removed via rinsing with 42 mL of binding buffer. 
Wash fractions (3 mL) were monitored by measuring optical density at 280 nm in a 
spectrophotometer (UV-1200 Shimadzu). The column was then returned to room 
temperature and, after addition of 3 mL of elution buffer, was incubated overnight (>16 h). 
An additional 42 mL of elution buffer was added to the column and 3 mL fractions 
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collected. Those with 0D 280 >0.015 were pooled and dialysed against 4 x 1 L changes of 
phosphate buffered saline (PBS; 5 mM Na 211PO4, 2 mM ICH 2PO4, 150 mM NaC1, pH 7.2). 
SpA-purified Ig was obtained using an Econo-Pac protein kit® (Bio-Rad) with an affinity 
column, 2 mL bed volume, and buffers supplied or, via a protein A-sepharose matrix, 1 mL 
bed volume, housed in a column using procedures and buffers described by Bollag et al. 
(1996). In the latter method barramundi serum was diluted 1:1 with starting buffer (100 mM 
tris-HC1, 100 mM NaCl, pH 7.5) then 0.2 pm filter sterilised. One millilitre of sample was 
applied to the column, overlaid with 0.4 mL of starting buffer and incubated for 30 min at 
room temperature. The column was then washed with 15 mL of starting buffer and 0D 280 of 
wash fractions monitored for contamination before application of 10 mL elution buffer (1 M 
glycine-HC1, pH 2.5) and incubation for 30 min. Eluent was collected as 1 mL fractions in 
tubes containing 0.1 mL of neutralising buffer (1 M tris-HC1, pH 8.0). Collected fractions 
with 0D280 >0.2 were pooled then either extensively dialysed against PBS or buffer 
exchanged through a desalting column previously equilibrated with PBS. 
Protein content of each Ig preparation was determined with a protein assay kit (Bio-Rad) 
using bovine gamma globulin (Bio-Rad) as a standard and purity was assessed using sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Where necessary, Ig in 
each preparation was concentrated using a centrifugal filter device (Ultrafree-15®, 
Millipore). 
2.2.2 Polyacrylamide gel electrophoresis 
Proteins in all Ig preparations were partially characterised by polyacrylamide gel 
electrophoresis (Laemmli, 1970) under both non-reducing and reducing conditions to 
determine purity, isomeric state and approximate molecular weights of native and reduced Ig 
molecules and components. Native preparations were diluted 4:1 in sample buffer (321.5 
mM tris, 50% glycerol, 0.05% bromophenol blue) and electrophoresed on 4 or 5% resolving 
gels with 3% stacking gels. Reduced samples were diluted at the same ratio in reducing 
sample buffer (60 mM tris, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 0.1% 
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bromophenol blue), heated to 100°C for 4 min then electrophoresed on 8 or 10% resolving 
gels with 4% stacking gels both containing SDS. All native samples were electrophoresed in 
buffer (25 mM tris, 192mM glycine) for at least 1 h with a current limit of 60 mA and at 200 
V. Reduced samples were electrophoresed for a similar time using the same buffer but with 
the addition of 0.1% wv -i SDS. Protein bands on gels were visualised after staining with 
either Comassie brilliant blue (CBB) (0.5% CBB, 50% methanol and 10% acetic acid) for 1 
h, then destained overnight in 10% methanol and 10% glacial acetic acid, or silver nitrate. 
Silver stain procedures were modified from those of Harlow and Lane (1988). Briefly gels 
were fixed with 50% ethanol and 10% glacial acetic acid for at least 30 min followed by 15 
min in 5% ethanol and 1% glacial acetic acid, rinsed 3 times in distilled water then bathed in 
0.2% sodium thiosulphate for 1 min. Gels were exposed to 0.2% silver nitrate with 0.15% 
formalin solution, rinsed in distilled water then developed in a solution of 6% sodium 
carbonate, 0.05% formalin and 0.2% sodium thiosulphate. Development was stopped with 
1.5% sodium EDTA. 
Molecular weights (MW) of heavy and light chain polypeptide components were determined 
from a plot of the log of molecular weights of known standards against the relative 
mobilities (RI) of these standards, where Rf is the distance migrated by the protein divided 
by the distance migrated by the dye (Hames and Rickwood, 1990). Reference standards 
were broad range molecular weight markers (Bio-Rad) or multicoloured standards (Novex) 
and at least 3 gels were used for each determination. For analysis of the whole molecule 
under native conditions standards were high molecular weight markers (Pharmacia) and 
human IgM donated from the Immunobiology Unit, University of Technology Sydney 
(UTS). 
2.2.3 Gel filtration 
Molecular weight of the whole barramundi Ig molecule was determined by gel filtration 
chromatography in a Sephacryl high resolution (S-300 gel type; Pharmacia) column with a 
fractionation range of 10-1500 kDa. Reference standard proteins were bovine serum 
albumin (66 kDa; Sigma), alcohol dehydrogenase (150 kDa; Sigma), apoferritin (443 kDa; 
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Sigma), thyroglobulin (669 lcDa; Sigma) and human IgM (950 lcDa; UTS). The column void 
volume (Vo) was 92 mL and 2 mL fractions were collected, the elution volume (Ye) was 
determined from the peak OD at 280 nm. The actual mass of the barramundi Ig molecule 
was estimated from a standard curve of logarithm of MWs of the standards against their Ve 
divided by Vo of blue dextran. 
2.2.4 Production of rabbit anti-barramundi immunoglobulin serum 
Rabbits were housed at the Central Animal House of the University of Tasmania, Sandy Bay 
Campus, Hobart. Duplicate rabbits were each injected intramuscularly at multiple sites with 
MBP-purified preparations of barramundi Ig (100 1.1g protein) diluted in sterile PBS (pH 7.2) 
with an equal volume of Montanide ® ISA-50 adjuvant as a 1.5 mL inoculum. Rabbits were 
boosted at days 28 and 62 as per initial injection. Blood samples from the lateral ear artery 
were taken prior to each injection and 30 days after the final booster. Rabbits that had been 
inoculated with MBP-derived Ig were given additional boosters of H and L chain Ig bands 
excised from SDS-polyacrylamide gels of MBP-derived product at days 180 and 202 then 
euthanased and bled at day 216. These additional boosters were prepared by running the 
MBP-derived product on 10% reducing polyacrylamide gels, excising the bands 
corresponding to H and L chains, then homogenising with saline and mixing with an equal 
volume of montanide adjuvant. They were administered as 1.7 mL inocula (approximately 
50 pg protein per inoculum) to each rabbit. These boosters were given in an attempt to 
selectively elicit antibodies directed against barramundi Ig. 
SpA-derived Ig (approximate protein concentration of 0.7 mg rrIL-1 ) was administered to 
duplicate rabbits as H or L chain Ig components excised from 10% reducing polyacrylamide 
gels of the PA product. Excised bands were dialysed against 4 x 1 L changes of PBS over 3 
days. Each rabbit was given a 1 mL inoculum containing approximately 112 [tg protein (H 
chain) or 28 lig protein (L chain) with equal volumes of montanide adjuvant. Injections were 
performed on days 0, 47 and 70. All rabbits were euthanased and bled on day 152. Resultant 
antisera are referred to as MBP 3 or 4, HC 1 or 2 and LC 1 or 2 with numbers denoting 
individual rabbits. 
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2.2.5 Immunoblotting 
Western blots were performed to assess specificity for barramundi Ig and cross reactivities 
with serum proteins from other teleost species. Firstly, either whole barramundi serum or 
SpA-purified barramundi Ig was diluted in a reducing sample diluent to approximately 100 
jig mI.: 1 protein, then proteins separated on SDS-PAGE (10% resolving gel and 4% stacking 
gel) under reducing conditions. The proteins were electrotransferred onto 0.45 um 
nitrocellulose membrane (MFS, USA) in transfer buffer (tris 48 mM, glycine 39 mM, 
methanol 20% vv - ') using a Semiphor®  semi-dry transfer unit with a maximum current 
setting of 0.8 mA cm' and a voltage limit of 60 for 1-2 h. Success of protein transfer was 
confirmed using a temporary total protein stain (0.1% ponceau S wv -I and 5% glacial acetic 
acid vv'; Sigma). Various lanes were then cut from membranes as strips to enable individual 
staining or probing with a range of dilutions of antisera. Temporary stains were removed by 
rinsing nitrocellulose strips in tris buffered saline (TBS; 20 mM ti -is, 500 mM NaC1, pH 7.5) 
for 5 min. Molecular weight standards were permanently visualised after staining with 
amido black (0.1% amido black 10B, 25% isopropanol, 10% glacial acetic acid) for 1 min 
then destaining (25% isopropanol, 10% glacial acetic acid) for 30 min (Gershoni and Palade, 
1982). Residual binding sites on nitrocellulose strips containing sera or Ig components were 
firstly blocked with 1% skimmed milk in TBS for 1 h, then washed with TBS, TBS-0.05% 
tween 20, then TBS again (5 min for each wash). Membranes were immersed in various 
antisera diluted in blocking buffer (1% skimmed milk in TBS) for 1 h. After repeating the 
washing step, membranes were immersed in goat anti-rabbit IgG (whole molecule) 
conjugated to horseradish peroxidase (Sigma) diluted 1:1000 in blocking buffer for 1 h. The 
washing step was repeated before reactive bands were visualised with 3,3' diaminobenzidine 
tetrahydrochloride (DAB) peroxidase substrate (Sigma). All steps were carried out at room 
temperature, and rabbit pre-bleeds in lieu of antisera were used as controls. In an effort to 
increase its specificity antiserum MBP 3 was applied to the SpA affinity column using the 
protocol described in section 2.2.1, it was then used to probe barramundi serum and Ig via 
immunoblots. The same electrophoresis and probing protocols were used to assess cross-
reactivites of various antisera with serum constituents of other species including: black 
bream, Acanthopagrus butcheri, southern bluefin tuna, Thunnus maccoyii, carp, Cyprinus 
29 
carpio, rainbow trout, Oncorhynchus mykiss, flounder, Rhombosolea tapirina , and Atlantic 
salmon, Salmo salar. 
2.2.6 Flow Cytometry and immunofluorescence 
Flow cytometry was used to assess the ability of various anti-barramundi Ig antisera to 
recognise lymphocytes with surface Ig (Ig+). Firstly, blood was obtained from a single 4.5 
kg adult barramundi held at the School of Aquaculture, University of Tasmania, Launceston 
via caudal puncture and collected in sodium EDTA tubes. Peripheral blood leucocytes were 
isolated from whole blood using density gradient centrifugation using a separation medium 
(Percoll®, Pharmacia) at densities of 1.035 g mL -1 layered onto 1.065 g mL-1 at 400 x g for 
30 min at room temperature. Leucocytes were collected at the interface of each density layer 
then twice washed in cell culture medium (RPMI ®, CSL Ltd.) by centrifugation for 10 min 
at 200 x g. Supernatant was then drawn off and cells were resuspended in 1 mL of medium. 
An aliquot of the suspension, mixed 1:1 with 0.5% solution of trypan blue, was, examined 
microscopically for cell viability and enumeration. Cell densities were adjusted to 4 x 10 8 
cells mL-1 and the suspension was divided as 0.5 mL aliquots to eppendorf tubes. Tubes 
were centrifuged for 5 s, supernatants removed and 50 jiL of each antisera, diluted to 1:100 
in cell culture medium supplemented with 0.1% fetal calf serum (Sigma) and 0.1% NaN 3 
(hereafter referred to as staining medium), was added to individual tubes before incubation 
at 4°C for 30 min. Cells were washed 3 times in staining medium before resuspension in 
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Immunotech, France) 
diluted 1:100 in staining medium and incubated as described before. Washing procedures 
were repeated 3 times before final resuspension of cells in staining medium containing 1% 
paraformaldehyde. Controls included the unmanipulated cell suspension, tubes containing a 
rabbit pre-bleed in lieu of anti-barramundi Ig antiserum and tubes containing all the reagents 
except the anti-barramundi Ig antiserum or the FITC-conjugated goat anti-rabbit Ig 
antiserum. Samples were analysed with a flow cytometer (FACScan ®, Becton Dickinson) 
and gated for cells with both low forward scatter (FCS) and side scatter (SSC) 
characteristics (i.e. lymphoid cells). 
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2.2.7 Enzyme-linked immunosorbent assay (ELISA) 
Standard ELISA methods were followed to detect anti-barramundi Ig antibodies in rabbit 
antisera or in rabbit pre-bleeds. Microtiter plates (Cellstar ®, Greiner Labortechnik) were 
coated in either barramundi serum or the SpA-derived barramundi Ig as antigens, residual 
binding sites in wells were blocked with 3% sodium casein in PBS solution before being 
overlaid with rabbit antisera, then finally overlaid with goat anti-rabbit Ig antiserum 
conjugated to horseradish peroxidase for detection with o-phenylenediamine. Initially, to 
optimise working dilutions, rabbit anti-barramundi Ig sera were titrated against SpA-purified 
barramundi Ig in typical chessboard titrations (Crowther, 1995). Firstly, antigens in coating 
buffer (50 mM sodium hydrogen carbonate, pH 9.5) were applied to a 96 well microtiter 
plate in a 2-fold serial dilution across 12 columns, starting at a protein concentration of 
approximately 40 vg mL -I for the SpA-derived Ig. After incubation overnight at 4°C excess 
fluid was removed from wells by flicking and firmly tapping inverted plates on a paper 
towel and all unbound sites in wells were then blocked with 3% casein in PBS during 
incubation for 1 h at 37°C. Plates were then washed 4 times with PBS buffer using an plate 
washer (Immunowash®, Bio-Rad) before the addition of antisera, diluted in blocking buffer 
(1% casein in PBS), down the rows in a 2-fold serial dilution beginning at 1:50 and 
incubated for 1 h at 37°C before washing as above. Goat anti-rabbit IgG (whole molecule) 
horseradish peroxidase conjugate (Sigma) diluted to 1:2000 in blocking buffer was then 
added to all wells and plates were again incubated for 1 h at 37°C. Following a final wash 
step, the horseradish peroxidase was activated with 0.05% o-phenylenediamine (OPD) free 
base (Sigma) solution in sodium citrate phosphate buffer (0.1 M citric acid, 0.09 M 
Na2HPO4, pH 5) with 0.012% H 202 . The reaction was stopped with 3 M (3 N) HC1 after 15 
min and optical density (OD) read with a microplate reader (Titertek, MS212) at 492 nm. 
All reagents were added to wells in volumes of 50 [IL. Chequerboard titrations were 
repeated using SpA Ig starting at 10 lig mL -1 protein as coating antigen and antisera at 
starting dilutions at 1:20. Once the minimum antigen concentration giving a significant 
0E1492 (around 1.5-2.0) was determined, all antisera were titrated in duplicate against this 
antigen concentration using the standard method as described above. 
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2.3 RESULTS 
2.3.1 Purification of barramundi Ig 
Yields of barramundi Ig from each isolation method were varied (Table 2.1). The affinity 
purified products had approximate protein concentrations between 34-58 jig mL -I (MBP-
derived product) and 200-700 pg mL -1 (SpA-derived product). The large range in protein 
concentrations of both products was possibly caused by differences in Ig levels of the serum 
samples used, variation in ambient laboratory conditions and multiple use of the columns. 
From the elution profiles it can be seen that barramundi Ig was eluted from the MBP column 
generally in the first 9-12 mL of the elution buffer, whereas the majority of Ig was contained 
in the first 3 mL of eluent from the SpA column (Figure 2.1). 
Table 2.1. Protein concentrations and yields of affinity chromatography purified barramundi 
Ig using either mannan-binding protein (MBP) or protein A (SpA) as capture ligands 
Capture ligand 	 Pooled eluent protein concentration (pg mL -I ) 
MBP 
	
45 
40 
34 
58 
PA 	 227 
700 
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2.3.2 Gel electrophoresis and gel filtration 
Polyacrylamide gels of reduced Ig products (Figure 2.2A) show that both PA- and MBP-
purified Ig contain 3 common bands at approximate MW of 108.4 ± 3.5 lcDa, 86.0 ± 5.8 lcDa 
and 24.2 ± 2.0 kDa, n = 3. MBP-purified Ig also contains a fourth band at 55.5 ± 2.7 lcDa. 
PA-purified Ig electrophoresed under non-reducing conditions (Figure 2.2B) showed that the 
complete Ig molecule forms one protein band suggesting a tetrameric structure in common 
with other teleost Ig and with a probable with a MW notably higher than 6691cDa. This was 
confirmed by gel filtration which showed that native Ig molecule had an approximate MW 
of 929 lcDa (Table 2.2). 
Table 2.2 Molecular weight (MW) of barramundi Ig estimated from a standard curve of the 
logarithm of MWs of standard proteins against the elution volume (Ve) divided by the void 
volume (Vo) of blue dextran after gel filtration. The linear equation for the standard curve 
was y = -2.2068x + 5.3187,e = 0.9402 and Vo was 92 mL 
Standard Ve VeNo Log MW MW (1cDa) 
Bovine serum albumin 142 1.543 1.820 66 
Alcohol dehydrogenase 132 1.435 2.176 150 
Apoferrtin 116 1.260 2.646 443 
Thyroglobulin 108 1.174 2.825 669 
Human IgM 92 1.000 2.978 950 
Barramundi Ig 98 1.065 2.968 929 
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Figure 2.1 Elution profiles of barramundi Ig from both the mannan-binding protein 
(MBP) and Staphylococcal protein A (SpA) affinity chromatography columns 
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2.3.3 Immunoblotting 
Western blots confirmed the specificity of all antisera, except LC 2, pith reduced barramundi 
serum components and with reduced SpA-purified barramundi Ig at dilutions up to 1:800 
(Figures 2.3-2.5). LC 2 was from a non-responsive animal and this antiserum had no further 
part in the analyses. When probing reduced SpA purified Ig all antisera were reactive with 
either or both H and L chain components and two other unidentified bands of approximately 
55 and 60 kDa, all rabbit pre-bleeds were also reactive with these bands and, at a dilution of 
1:100, MBP 3 was reactive with a protein band which had a molecular weight 
approximating that of the H chain (Figure 2.6). When probing serum however, rabbit pre-
bleeds were negative. Appearance on the blots of a reactive protein bands in the SpA 
purified Ig and not the barramundi serum suggests that they were contaminants from the 
SpA column itself, and reactivity with pre-bleeds indicates the possibility of contaminants 
being SpA. Some leaching of the ligand from the sephadex is not unique (Knicker and 
Profy, 1991; Godfrey et al., 1992; Steindl et al., 2000) and has been investigated by 
colleagues in our laboratory (Morrison and Nowak, 2000). 
Reactivity with other serum proteins of MBP-derived antisera led to attempts to remove 
irrelevant antibodies from these samples. This was attempted by adsorption, which tended to 
remove all antibody activity and, application of MBP 3 through the protein A affinity 
column. This latter method proved to be relatively effective as subsequent Western blots of 
the purified antisera (Figure 2.7) show that at a 1:200 dilution reactivity was restricted to the 
heavy chain component of the barramundi Ig and thus this antisera may be a useful ELISA 
reagent. 
Though background reactivity of HC 1 and 2 and LC 2 antisera was noted with serum 
proteins other than Ig, this was removed at dilutions higher than 1:400. Therefore, these 
antisera are potentially useful in immunoassays as markers for barramundi Ig. 
Investigations into cross-reactivity of various antisera with serum proteins from other fish 
species showed consistent activity with southern bluefin tuna (Figures 2.8-2.10). Moieties in 
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the tuna serum corresponding in molecular weight to H and/or L chain Ig are clearly visible 
after probing with MBP 3, HC 2 and LC 1. Additionally MBP 3 appears reactive with 
similar moieties in rainbow trout serum and MBP 4 seems reactive with both the rainbow 
trout and Atlantic salmon H chain moiety. 
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Figure 2.2 Electrophoretic profiles of heterologous lg. A. SDS-PAGE analysis in 
10% gel under reducing conditions comparing MBP-purified barramundi  Ig (lane 1) 
with SpA-purified barramundi Ig (lane 2). B. PAGE analysis of native Ig molecules 
on a 5% gel under non-reducing conditions comparing MEP-purified barramundi Ig 
(lane 1), snapper Ig (lane 2), SpA-purified barramundi Ig (lane 3), human  IgM (lane 
4) and Atlantic salmon Ig (lane 5). Both gels were silver stained 
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Figure 2.3 Western blot analysis of rabbit anti-barramundi Ig antisera showing 
reactivity with heavy chain components of reduced SpA-purified barramundi Ig (lanes 
2, 4 &6) and barramundi serum (lanes 1, 3 & 5). Probing antisera dilutions were 1:200 
(lanes 1 & 2), 1:400 (lanes 3 &4) and 1:800 (lanes 5 & 6). A. MBP 3 B. MBP 4 
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Figure 2.4 Western blot analysis of rabbit anti-barramundi Ig antisera showing 
reactivity with heavy chain components of reduced SpA-purified barramundi Ig (lanes 
2, 4 &6) and barramundi serum (lanes 1, 3 & 5). Probing antisera dilutions were 1:200 
(lanes 1 & 2), 1:400 (lanes 3 &4) and 1:800 (lanes 5 & 6). A. HC 1 B. HC 2 
39 
pig 
MW 
kDa 
116 IIr 
97 
66 11101"--• 
45 0100-' 
31 illo" 
21 	jo, 
14  
123 	4 	5 	6 
Figure 2.5 Western blot analysis of rabbit anti-barramundi Ig antisera (LC  1) showing 
reactivity with heavy chain components of reduced SpA-purified barramundi Ig (lanes 
2, 4 &6) and barramundi serum (lanes 1, 3 & 5). Probing antisera dilutions were 1:200 
(lanes 1 & 2), 1:400 (lanes 3 &4) and 1:800 (lanes 5 & 6). 
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Figure 2.6 Western blot analysis of rabbit pre-bleeds showing reactivity with SpA-
purified barranumdi Ig. Pre-bleeds were 1:100 and 1:200 in consecutive lanes; HC 1 
(lanes 1 & 2), HC 2 (lanes 3 & 4), LC 1 (lanes 5 & 6), MBP 3 (lanes 7 & 8) and MBP 
4 (lanes 9 & 10) 
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Figure 2.7 Western blot analysis of rabbit anti-barramundi Ig (MBP 3) after 
application of the antiserum through the SpA affinity chromatography column as an 
attempt to increase specificity for barramundi Ig. Lanes 2, 3 and 4 contain barramundi 
serum, SpA-purified barramundi Ig and MBP-purified barramundi Ig respectively and 
were probed with the antiserum at a dilution of 1:100. Lanes 5, 6 and 7 contain the 
same serum and purified Ig and were probed with the antiserum at a dilution of 1:200 
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Figure 2.8 Cross-reactivities of rabbit-anti barramundi Ig with heterologous sera, 
lanes: 1-black bream, 2-southern bluefm tuna, 3-carp, 4-rainbow trout, 5-flounder, 6- 
Atlantic salmon and 7-barramundi. A. Probed with HC 1 at 1:200 B. Probed with 
HC 2 at 1:200 
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Figure 2.9 Cross-reactivities of rabbit-anti barramundi Ig with heterologous sera, 
lanes: 1-black bream, 2-southern bluefin tuna, 3-carp, 4-rainbow trout, 5-flounder, 6- 
Atlantic salmon and 7-barramundi. A. Probed with MBP 3 at 1:200 B. Probed with 
MBP 4 at 1:200 
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Figure 2.10 Cross-reactivities of rabbit-anti barramundi Ig with heterologous sera, 
lanes: 1-black bream, 2-southern bluefin tuna, 3-carp, 4-rainbow trout, 5-flounder, 6- 
Atlantic salmon and 7-barramundi. A. Probed with LC 1 at 1:200 B. Probed with LC 
2 at 1:200 
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2.3.4 Flow cytometry 
Forward scatter versus side scatter profiles and frequency histograms (Figures 2.11 & 2.12) 
show the gated cell populations analysed and subsequent proportions of fluorescing cells. 
Much of the apparent debris was unavoidable in this instance due to the time between 
incubations of cells with antibodies and actual cell counting with the cytometer 
(approximately 8 h). Fluorescence of proportions of gated cells show that all antisera are 
capable of binding to lymphocytes, with the percentage of total lymphocytes staining 
positive varying between each reagent (Table 2.3). All control cells sets were negative. 
Antisera HC 1 and 2 seem to show higher degrees of specificity relative to MBP antisera 
which tended to react with higher percentages of lymphocytes. 
Table 2.3. Percentage of total barramundi lymphocytes detected by flow cytometry after 
incubation with various rabbit anti-barramundi Ig antisera 
Antisera 	 Percentage of lymphocytes fluorescing 
MBP 4 	 91.3 
MBP 3 	 73.5 
HC 1 	 61.3 
HC 2 	 52.6 
LC 1 	 69.3 
2.3.5 ELISA 
The minimum SpA Ig level chosen from the chequerboard titrations for antisera titrations 
giving OD 492 between 1.5 and 2 was 0.625 pg mL 1 (Figure 2.13). Subsequent antisera 
titrations curves (Figure 2.14) show MBP antisera with substantially higher anti barramundi 
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Ig activity than either HC and LC antisera. MBP 3 antisera titered out between 40960 and 
81920 (reciprocal dilution) whereas HC 1 and LC 1 were between 320 and 640 and HC 2 
was between 2560 and 5120. Given the titers and specificities of each antisera SpA-purified 
MBP 3 and HC 2 were chosen as antisera to use in ELISAs to detect antigen specific 
barramundi Ig. 
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Figure 2.11 Forward scatter/side scatter profiles of peripheral blood leucocytes showing 
the gated cell population (presumed lymphocytes and frequency histograms indicating 
F1TC+ cells after incubation with various rabbit anti-barramundi Ig antisera and 
subsequent binding with FITC-conjugated goat anti-rabbit Ig antiserum. A. 
Unmanipulated PBLs B. PBLs incubated with MBP 3 C. PBLs incubated  with MBP 4. 
47 
200 	100 	000 	$00 	1000 
Fsc-H 
0 
0 
A 
  
  
 
M*1 
6 	zoo 	460 	660 	$60 lobo 
FSC-H 
  
10 	 10 	 10 	 10 
FL 1-1-I 
 
M1 
 
100 	 10' 
. 1 
I 2 	 10'3 	 10" 
. A 
ELI-H 
266 	466 	666 	"*66 "iVoo 
FSC-H 
Figure 2.12 Forward scatter/side scatter profiles of peripheral blood leucocytes showing 
the gated cell population (presumed lymphocytes and frequency histograms indicating 
FITC+ cells after incubation with various rabbit anti-barramundi Ig antisera and 
subsequent binding with FITC-conjugated goat anti-rabbit Ig antiserum.  A. PBLs 
incubated with HC 1 B. PBLs incubated with LC 1 C. PBLs incubated with HC 2. 
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Figure 2.13 Titration curves of SpA-purified barramundi Ig antigen against a single dilution 
of each rabbit anti-barramundi Ig antisera and pre-bleeds showing 0.625 pg mL -1 as the 
antigen protein concentration chosen to titrate each antiserum. (a) HC 1, HC 2 and LC 1 at 
1:20 dilution. (b) MBP 3 and MBP 4 at 1:2560 dilution. 
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Figure 2.14 Titration curves of various anti-barramundi Ig antisera serially diluted from 1:5 
to 1:2.1 x 107 against a constant concentration (0.625 pg mL - I protein) of SpA-purified 
barramundi Ig. Values are means + SE (n = 2). 
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2.4 DISCUSSION 
Purification of the barramundi serum immunoglobulin was most successful in terms of yield 
and purity using the SpA affinity chromatography column. Affinity chromatography using 
SpA as the capture ligand has been demonstrated to be effective in isolating IgM from the 
serum of several fish species including carp, C. carpi°, (Zikan et al., 1980: Suzuki et al., 
1990), goldfish, Carassius auratus, yellowtail, Seriola quinqueradiata, red sea bream or 
snapper, Pagrus auratus, (Suzuki et al., 1990; Morrison and Nowak, 2000), turbot, 
Scophthalmus maximus, (Estevez et al., 1993; Fournier-Betz, 2000), seabass, Dicentrarchus 
labrax, (Scapigliati et al., 1996), southern bluefin tuna, T. maccoyii, (Watts 2000) and 
several Antarctic fish species (Scapigliati et al., 1997). Conversely, the use of MBP as a 
capture ligand has had limited use in isolating serum Ig from fish, although it has been used 
to purify IgM from rainbow trout, 0. mykiss ,(Kehrer, 1995) and tomato clownfish, 
Amphiprion frenatus, (Cobb et al., 1998). Reasons for the limited use of MBP are unclear 
but certainly the comparatively low yield using this ligand to purify barramundi serum Ig 
noted in this study makes it a less attractive option as a capture ligand. In this case the SpA 
column resulted in a yield which was in the order of 10 times greater than that achieved 
from the MBP affinity column and seemed to be a more pure product. Yield variation 
between batches from the same column may probably be attributed to differences in 
conditions, Ig levels in serum samples or multiple use, but reasons for yield differences 
between columns are not so clear. 
Although it seems that SpA is more efficient in purifying barramundi serum Ig in this study 
direct comparisons of the IgM binding ability of the two ligands cannot be made mainly 
because of different column capacities and variation of serum samples. Regardless of the 
efficiencies of either ligand both have been shown to suitable and relatively simple methods 
for the isolation of barramundi Ig. It was important to investigate binding ability of these 
proteins with barramundi Ig as SpA at least has variable capacity to bind with Igs from 
different fish genera (Estevez et al., 1993). 
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The possible sample contamination of barramundi Ig with SpA was a concern, particularly 
for in vivo administration given its potential toxicity (Besinger et al., 1984), however, for the 
purpose of this study the contamination is of lesser importance. To produce anti-barramundi 
Ig in rabbits only protein bands corresponding in MW to H and L chain components of SpA-
derived Ig were excised from polyacrylamide gels were used as inocula. SpA-derived Ig was 
used for molecular weight estimations of the whole molecule and H and L chain 
components. What does not concur with the theory of SpA leaching into the samples is the 
absence of bands on the polyacrylamide gels that correspond in molecular weight to those 
seen on the blots (approximately 60-66 kDa) and further the molecular weight of SpA is 
around 42 kDa. Molecular weight discrepancies between SpA and the presumed 
contaminating SpA seen on blots may be a result of coupling of SpA and Ig residues leading 
to an apparently higher molecular weight. The strongest evidence that SpA was leached 
from the column used in this study was Western blot analysis of elution buffer without the 
addition of serum that showed protein bands reactive with rabbit anti-snapper, P. auratus, Ig 
antiserum, rabbit pre-bleeds and HRP-conjugated goat anti-rabbit Ig antiserum (Morrison 
and Nowak, 2000). This suggests that contaminating proteins had an affinity for mammalian 
IgG which is a characteristic of SpA (Kronvall et al., 1970). 
Molecular weight analysis by SDS-PAGE under reducing conditions and by PAGE under 
native conditions showed that as with most teleost Ig studied to date barramundi Ig appears 
to be made up of HC and LC moieties. Although reported MWs are generally in the region 
of 70-81 and 23-28 kDa for HC and LC respectively for teleosts, in this study gels indicated 
MWs of 86 and 24 kDa for HC and LC. Compared to MWs previously reported for 
barramundi of 70 kDa and 24 kDa (Bryant et al., 1999), there is substantial discrepancy with 
HC. This may be due to differences between samples, protocols or standard reference 
markers used, or possibly to anomalous migration of the H chain during SDS-PAGE due to 
high glycosylation as reported by Wilson et al. (1985) in goldfish, C. auratus. Molecular 
weight of native barramundi Ig can be confirmed by gel filtration. However, given the 
approximate values of H and L chains the MW of the native molecule would be 
approximately 880 kDa. This assumes a tetrameric structure for barramundi Ig which is 
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characteristic of many teleost Igs (Acton et al, 1971; Lobb and Clem, 1981), and was 
implied by electrophoresis under non-denaturing conditions (Figure 2.2B). 
Specificities of the various rabbit anti-barramundi Ig antisera, investigated by Western blots 
revealed that MBP 3 and 4 were reactive with a number of serum proteins including both 
those presumed to be the H and L chain components. However, HC 1 and 2 and LC 1 were 
more specific for barramundi Ig to the point where HC 1 and 2 did not react with the L chain 
and LC 1 did not react with the H chain suggesting a lack of antigenic similarity between 
both Ig components. Application of MBP 3 antiserum to a SpA affinity chromatography 
column improved its specificity and at dilutions of 1:200 was only reactive with the H chain 
Ig moiety. This process effectively isolated the IgG component of the antiserum and 
removed any extraneous proteins which may have interfered with immunoassays. 
Assessment of cross-reactivity with serum components from other species revealed that HC 
2, LC 1 and MBP 3 reacted with components from tuna Ig of the same MW as barramundi 
HC and LC, i.e. approximately 86 and 24 kDa respectively. Heavy and light chain moieties 
in purified tuna Ig appear as doublets on polyacrylamide gels with approximate MWs of 
71.2 and 74.6 lcDa for the H chain and 28 and 29 lcDa for L chain respectively (Watts, 
2000). This discrepancy in MWs may indicate either that bands visible in the tuna serum are 
not Ig or, may be due to differences in experimental technique. For example, in this study 
MWs are inferred from markers transferred to nitrocellulose from one gel only and not 
replicated gels as reported by Watts (2000). Also, migration patterns of purified Ig may vary 
from those of Ig in a whole serum environment. In any case, further characterisation of 
cross-reactivities is required to elucidate the potential value of these antisera in work on 
other species. 
Immunofluorescence measured by flow cytometry demonstrated reactivity of all antisera 
with sub-populations of gated peripheral blood lymphocytes (PBLs) although percentages of 
fluorescing cells vary between each. MBP-derived antisera appears to be cross-reactive with 
T cells with percentages of reactive cells within PBLs (73.5 and 91.3%) higher than for 
SpA-derived antisera (52.6-69.3%) which is indicative of the higher specificity for Ig of HC 
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1 and 2 and LC 1. However, common observations made are that mammalian polyclonal 
antibodies to purified Ig from various fish species are reactive with all fish lymphocytes 
(Miller et al., 1998). This cross-reactivity has been attributed to the existence of 
anticarbohydrate antibodies in the antiserum and their reaction with surface glycoproteins 
and glycolipids on both B and T cells (Yamaga et al., 1978). Whether or not the reactive 
cells in this study were solely Ig+ is not certain though percentages of reactive cells in PBL 
of barramundi elucidated by SpA-derived antisera are, in some cases, only slightly higher 
than reported for other teleost species when stained with various mAbs such as 46% in 
rainbow trout, 0. mykiss, (DeLuca et al., 1983; Sanchez et al., 1993), 35-51% also in 
rainbow trout (Thuvander et al., 1990) and 21 - 31% in sea bass D. labrax (dos Santos et al., 
1997). Polyclonal antibodies by definition are not monospecific and therefore cross-
reactivity is expected, however, mAbs used in the studies cited above are specific for an 
individual epitope on the H chain. Given the isotypic variation within both H and L chain Ig 
constituents in some teleosts (Lobb et al., 1984; Lobb and Olson, 1988) mAbs may not be 
reactive with all Ig+ cells thus percentages quoted possibly underestimate proportion of Ig+ 
cells in PBLs. In this study flow cytometry was used to assess the ability of anti-barramundi 
Ig antisera to react with Ig+ cells and thus provide additional evidence as to the specificities 
of the antisera. Results indicate this to be the case for the SpA-derived antisera. Although 
some caution in interpretation is required as some Ig+ cells may be monocytes with serum Ig 
bound via the Fc receptor (Morrison et al. submitted). 
ELISA results of the characterisation of various antisera indicate that MBP-derived Ig 
elicited far greater responses in rabbits than SpA-derived Ig. This may be due to the kinetics 
of the rabbits' response, individual variation and the slightly variable protein levels in each 
inoculum, MBP Ig immunised rabbits had a longer time to respond as they were terminally 
bled at day 216 after initial immunisation compared to day 152 for SpA Ig immunised 
rabbits. The MBP Ig was also injected into rabbits as the whole product subsequently 
containing all the impurities, whereas SpA Ig was injected in reduced form as either H or L 
chain which may explain the better specificity of the SpA Ig-derived antisera. 
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Given the sensitivities and specificities of all antisera characterised, MBP 3 and HC 2 were 
chosen for use in immunoassays to detect antigen-specific antibody in barramundi after 
immunisation. 
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CHAPTER 3 
GENERAL MATERIALS AND METHODS 
3.1 INTRODUCTION 
This chapter details the materials and methods that recur throughout reports of each 
experiment. Two experiments were carried out where barramundi were immunised with a 
formalin-killed Vibrio harveyi cell suspension (bacterin) via: 1. intraperitoneal (IP) injection 
or immersion (IMM) and, 2. IP injection, anal intubation (AI) or IMM. In a third experiment 
barramundi were immunised by IP injection with either bacterin or lipopolysaccharide 
extracted from V. harveyi. Materials and procedures that are unique to a particular chapter or 
deviate from those described below appear in the relevant sections. 
3.2 FISH HUSBANDRY 
Barramundi (Lates calcarifer) were purchased from West Beach Aquaculture, Wingfield, 
South Australia and held in a static systems consisting of 140 L glass aquaria containing two 
airlift pumps and bottom gravel biofilters. Fish were held in seawater (35 ppt) at 25.7 ± 0.5° 
C (10-12 fish per tank), fed a commercial feed (Gibsons) at 2% body weight per day and 
acclimated over 4-6 weeks. Temperature and salinity were measured daily and water quality 
including total ammonia, nitrite, pH and dissolved oxygen monitored every 3-4 days. Tanks 
were cleaned as required with 50% water exchanges occurring at least every week. Total 
ammonia levels never exceeded 0.25 mg LI and if nitrite levels exceeded 2.0 mg L - ' water 
exchanges were carried out, both pH and dissolved oxygen remained relatively constant at 
approximately 7.3 ± 0.2 and 6.4 ± 1.4 mg L - ' (i.e. approximately 100% saturation) 
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respectively. Although it would be ideal to minimise any possible confounding factors, such 
as exposure to environmental bacteria of the genus Vibrio, by holding the barramundi in 
freshwater they were held in seawater in accordance with current and future production 
conditions in Australia where the majority barramundi are reared in seawater (C. Foster pers 
comin). 
Before immunisations, tanks were randomly assigned a treatment via a lottery method and 
fish were similarly randomly allocated to tanks and weighed at the beginning of each 
experiment. For any treatment requiring individual handling of fish, ethyl-p-aminobenzoate 
(benzocaine) at 70 mg L - ' was used as an anaesthetic. 
3.3 BACTERIN PREPARATION AND ADMINISTRATION 
Two strains of V. harveyi (designated 9056681 and 9050405) were isolated and 
characterised by Dr Lachlan Harris of James Cook University, Townsville, Queensland and 
were made available by Dr Jeremy Carson from the Department of Primary Industries, 
Water and Environment, Mount Pleasant Laboratories, Launceston, Tasmania. Bacteria were 
grown on Oxoid nutrient broth no.2 (NB2) supplemented with NaCl to 1.5% as 2 L volumes 
in 3 L flasks on a shaking water bath at 22°C for 72 h or 30°C for 24 h to densities of 
approximately 108 cells mL-1 as determined by hemocytometer counts. Cultures were then 
inactivated with formalin to a final concentration of 0.5%, returned to the water bath 
overnight (approximately 15 h) and finally stored in sealed sterile bottles at 4°C until 
required. Immediately prior to inactivation with formalin cultures were plated to horse blood 
agar to ensure uniform colonial morphology and culture purity. After inactivation sterility 
was confirmed by incubating 1-2 mL cell suspension aliquots in 15 mL of fresh salt 
supplemented NB2 medium at 22°C for 4 days then attempting to subculture onto horse 
blood agar plates. Additional checks were made using plates of the same medium inoculated 
after cells had been rinsed 3 times in saline. Cell densities of subsequent batches of bacterin 
were estimated from a standard curve (Figure 3.1) of cell numbers, determined by duplicate 
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hemocytometer cell counts, versus optical density at 550 nm measured on a 
spectrophotometer (UV 1200, Shimadzu). 
To prepare inocula for IP injection and Al cultures were centrifuged at 1000 x g for 15 min 
and cells harvested then washed twice in sterile saline (0.15 M NaC1) and recollected after 
centrifugation as above. Harvested wet weight was defined as the wet weight of pellet with 
supernatant removed. Cells were then suspended in sterile saline to a wet weight 
concentration enabling administration to fish at a dose approximating 0.08-0.1 mg of cells 
per g of fish. In the experiments barramundi were administered bacterin or sterile saline 
placebo via IP injection in volumes ranging between 0.1 and 0.4 mL depending on fish size 
which ranged from 52-95 g. AnaIly intubated fish (mean weight 93.6 g ± 14.4 g) were 
starved for 48 h prior to immunisaton and received bacterin or a placebo as 0.3 mL volumes 
via a flexible silicon tube attached to an 18 gauge needle and inserted approximately 5 cm 
along the intestine. The rationale was that bacterin would move further along the intestine on 
expulsion from the syringe but may also flow back toward the anus on removal of the silicon 
tube. Some back flow of bacterin from the anus was observed after removal of the tube. 
Prior to immunisation a single fish was sacrificed and dissected to ascertain length of 
intestine which was 7.8 cm. For IMM immunisation, inactivated cultures were diluted 1:5 
with seawater (35 ppt at 26°C) with no rinsing or harvesting of cells. Pairs of fish in dipnets 
were immersed for 60 s in 6 L of dilute vaccine (approximately 2 x 107 cells mL-1 ) in a 10 L 
container with aeration then transferred to a container to rinse off excess bacterin before 
being returned to holding tanks. To facilitate easy removal of fish from holding tanks, water 
levels were lowered and 50% water changes carried out. Control fish were handled 
identically and dipped in 6 L of seawater and then moved to another container as above. 
To acquire standard barramundi anti-V. harveyi antisera to both strains of the bacterium as 
positive controls and provide reference specific antibody activity, barramundi were 
immunised with either strain. For strain no. 9056681, a 4 kg barramundi was IP injected 
with a 140 mg dose of bacterin in an equal volume of Montanide ® ISA-50 adjuvant, then re-
immunised 11 weeks later and bled after a further 2 weeks. For strain no. 9050405, six fish 
(95 ± 12 g) were each IP injected with 8 mg of bacterin in an equal volume of Montanide ® 
58 
ISA-50 adjuvant, re-immunised after 4 weeks, then serum was harvested after a further 2 
weeks. 
3.4 SAMPLING PROCEDURES 
Prior to sampling fish had been starved for at least 48 h. Fish were lethally anaesthetised 
with benzocaine at 200 mg L - ', and samples taken as follows. Skin mucus was collected by 
gently scraping the skin from the operculum to the caudal peduncle with either the blunt 
edge of a scalpel blade or a cane skewer and immediately placed in 1.5 mL tubes containing 
0.5 mL of borate buffer (0.2 M boric acid, 0.05 M sodium tetraborate, pH 7.8) with protease 
inhibitors [1 mM phenylmethyl-sulphonylfluoride (PMSF), 5 mM iodoacetamide and 0.02% 
NaN3], (Ainsworth et al., 1995), then placed on ice. Blood was collected in syringes via 
caudal puncture using 27 gauge needles or, in blood tubes after severing the tail then 
allowed to clot at 4°C overnight. The following day serum was drawn off and stored at - 
20°C until assayed. Due to the occasional difficulty in obtaining blood samples by caudal 
puncture tail severing was the only means to access blood. Gut mucus was collected after a 
5-6 cm section of the intestine, cut approximately 0.5-1 cm anterior to the anus and 1-1.5 cm 
posterior to stomach, was removed and mesentery tissue gently scraped from the organ. One 
millilitre of borate antiprotease buffer was then cycled through the section of intestine at 
least 12 times, collected in 5 mL tubes, then immediately placed on ice. All mucus samples 
were frozen at -20°C within 8 h of sampling. Dissected kidneys were kept in fish 
physiological saline (FPS: 0.11 M NaCl, 0.15 mM KC1, 0.2 mM CaC1 2, 0.1 mM MgSO4 , 
0.05 mM KH 2PO4 , 0.12 mM NaHCO 3) in ice until macrophage collection. 
Some aspects of the sampling procedures require comment. Blood sampling via caudal 
puncture was, at times, very difficult and often delivered very small volumes which then 
limited the number of assays which could be performed using serum. This was the case in 
the experiment described in Chapter 4 and in the circumstances severing the tail was the 
only means to get blood. This is not ideal practice as water, mucus and urine from the fish 
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may contaminate the sample and have a diluting effect. Care was taken to prevent 
contamination by wiping water and mucus from the fish and positioning the blood tube 
under the severed caudal vein so as to preclude entry of any fluids seeping from the vent. In 
subsequent experiments caudal puncture via the lateral or ventral surface was a far more 
consistent means of extracting blood. 
Skin and gut mucus samples were collected using simple methods. Although other 
techniques for collecting cutaneous mucus using filter paper (Lobb and Clem, 1981; Lobb, 
1987; Zilberg and Klesius, 1997), cotton wool buds (Jenkins et al., 1994) and, allowing fish 
to shed mucus after being placed into small plastic bags with water (Wong et al., 1992) have 
been described, careful scrapping of the skin was a simple and efficient way to collect 
cutaneous mucus. Previously reported methods for collecting gut mucus include collecting 
faeces from the intestine (Rombout et al., 1986; Ainsworth et al., 1995), anal intubation (Al-
Harbi and Austin, 1992b), gut washings (Ainsworth et al., 1995) and stroking the exposed 
lumen of the gut wall with cotton buds (Lavelle et al., 1997). In the experiments described 
here gut mucus was collected by repeatingly flushing a section of intestine with a small 
volume of buffer, this effectively collected the gut contents, although faeces were absent due 
to the 48 h fasting period. As fish lack IgA which is resistant to proteolytic degradation after 
secretion into the gut lumen (Ellis, 1995) both skin and gut mucus samples were stored in 
buffer containing anti-proteases to prevent any Ig degradation due to proteases in the mucus 
secretions. 
3.5 IMMUNE ASSAYS 
3.5.1 Macrophage isolation 
Leucocytes were harvested from excised anterior kidneys by firstly pushing kidney material 
with Leibovitch medium (L-15; Sigma), supplemented with 1 mL L - ' barramundi serum, 
through a fine stainless steel mesh with a syringe plunger then homogenising in 7 mL glass 
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tissue grinder (Wheaton). L,eucocytes were isolated from homogenised material via density 
gradient centrifugation using a separation medium (Percoll®, Pharmacia) at densities of 
1.030 g inL1 layered onto 1.065 g m LI at 400 x g for 30 min at room temperature. Cells 
were collected at the interface of each layer, washed twice in 3-4 mL of L-15 before final 
resuspension in FPS. Cell counts and viability were determined using a 0.5% trypan blue 
solution mixed 1:1 with an aliquot of the cell suspension and a hemocytometer, then cell 
densities were adjusted to 4 x 106 viable cells mL -1 .To determine percentages of 
macrophages cell suspensions were smeared onto glass slides, air dried and stained (Diff 
Quick®, Pathtech), then differential cell counts performed. 
3.5.2 Phagocytic activity 
Phagocytic activity of the macrophage suspension was determined using a technique based 
on that of Seeley et a/.(1990). Fifty microlitres of the macrophage suspension was incubated 
with 100 [IL of congo red-stained yeast cells on a glass slide. Yeast cells were prepared by 
hydrating 0.22 g dry yeast with 24 mL phosphate buffered saline (PBS; 10 mM Na 2HPO4, 3 
mM KH2PO4, 0.12 M NaC1, pH 7.2) staining with 1 mL congo red, incubating for 5 min then 
autoclaved for inactivation. Cells were rinsed three times in PBS then the concentration 
adjusted to 10 8 cell mL-1 . After incubation at 22°C for 2 h, the suspension was mixed on the 
slide and cells were counted at 1000 x magnification. Results are expressed as the 
phagocytic index (i.e. % of cells containing 1 or more yeast cells) with a minimum of 100 
cells counted. 
3.5.3 Lysozyme assay 
Lysozyme levels in sera samples were measured by a turbidometric assay (Thompson et al. 
1994) where the activity of lysozyme is determined from a standard curve indicating the 
degree of lysis of Micrococcus lysodeikticus (Sigma) by known concentrations of hen egg 
white lysozyme (Sigma). One hundred and seventy five microlitres of a M. lysodeikticus 
suspension (75 mg in 100 mL of 0.1 M phosphate/citrate buffer with 0.09% NaC1, pH 6.0) 
was added to quadruplicate wells of a microtiter plate containing 25 111, of either sera 
samples or hen egg white lysozyme standards (0-20 Kg mL - I). After immediate plate shaking 
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optical densities at 450 nm were recorded at 5 min intervals in a multiscan plate reader 
(MCC/340 Titertek MultiskanO) to measure the rate of cell lysis relative to wells containing 
suspensions of M. lysodeikticus only. Optimal pH of 6.0 for the phosphate/citrate buffer was 
determined after measuring lysozyme in standard barramundi sera and the reference standard 
(hen egg white lysozyme) over a pH range of 5 to 8 with 0.5 increments (Figure 3.2). 
3.5.4 Enzyme-linked immunosorbent assay (ELISA) 
The standard indirect ELISA protocol using buffers and equipment described in section 
2.2.6 was followed to detect specific antibody in all barramundi serum samples. In this 
project, two different strains of V. harveyi were used for immunisations in different 
experiments which necessitated ELISA protocols using either strain as appropriate for 
coating antigens. Similarly, two different rabbit anti-barramundi Ig antisera were used for 
detection of specific barramundi antibody (MBP 3 and HC 2). V. harveyi strain no. 9050405 
was used as it superceded strain no. 9056681 in terms of virulence, and a second antiserum 
was used as it was more specific. Consequently, concentrations of both sets of reagents 
required optimising before use. The details of these optimisations are described in the 
Materials and Methods section of the relevant Chapters. 
Samples from each experiment were titrated in duplicate between dilutions of 1:50-1:1600 
and 1:100-1:3200 and all ELISA plates included both immune and non-immune standards. 
Anti-V. harveyi antibody activities were quantified using the method described by Arkoosh 
and Kaattari (1992), where the activity of a sample is calculated relative to the activity of the 
immune standard and is expressed as units of antibody activity per volume of serum. To 
ensure that the OD was proportional to the reaction rate within each well a kinetic analysis 
was performed where absorption was measured after the addition of OPD and subsequent 
development at 450 nm every minute for 15 min prior to stopping the reaction with addition 
of HC1 (Figure 3.3). Thus the development incubation period of 10 min was set. 
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Figure 3.1 Linear regression of absorbance at 550 nm versus Vibrio harveyi (strain no. 
9050405) cells mL-1 (log .0). Values are means + SE, n = 2, r2 = 0.998. 
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Figure 3.2 Lysozyme activity of barramundi serum measured at a range of pH against hen 
egg white standard showing maximum at pH 6.0. Barramundi serum was from non-treated 
fish and was assayed in quadruplicate. Values are means + SE. 
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Figure 3.3 Colour development and subsequent optical density at 405 nm over 
an incubation period of 15 min in an ELISA to quantify anti-V. harveyi activity 
in barramundi serum. A linear relationship is indicated over this period. 
Immunised and non-immunised sera samples were run in duplicate. Values are 
means + SE. 
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3.5.5 Bacteriostatic assay 
The bacteriostatic assay was modified from that of Thompson et al., (1994). In this case, V 
harveyi suspension was grown to a density of approximately 5 x 108 cell mL- I. Bacterial 
culture was initiated by inoculating 120 mL of NB2 with a cryopreservation bead (stored at 
-80°C) of the bacterium, grown overnight then inoculated into fresh media (3 mL). After 
incubation at 30°C in a shaking water bath for 2-2.5 h the cultures were in logarithmic 
growth phase. Cell densities were approximated from a standard curve constructed from a 
plot of log io of cell densities versus absorbance at 550 nm measured during the growth phase 
of the bacteria. Seventy five microlitres of this culture was incubated with 25 1.d. of sample 
sera in 96 well flat bottom microtiter plates at 24°C for 1 h after which 100 11, of 3-(4, 5- 
dimethylthiozol-2-y1)-2, 5-diphenyltetrazolium bromide; thiazol blue (MTT- 5 mg mL 1 
H20) diluted 1:10 in NB2 was added to each well, OD was immediately read at 550 nm and 
again after 15 min in the dark at room temperature with shaking. Differences in OD of 
samples and pooled non-immune standard barramundi sera standard (A0D) were calculated 
and antibacterial activity was determined by the formula : 
[(AOD non-immune standard - AOD sample) MOD non-immune standard] x 100 
Results are expressed as a percentage inhibition of V. harveyi relative to the non-immune 
pooled standard sera. Samples were assayed in triplicate and all plates had pooled immune 
(I.S.) and non-immune sera standards (N.I.S.). In the standardisation of this assay, both 
immune and non-immune controls were tested for differences due to heat treatment and 
consequent complement inactivation. The standards were heated in a water bath to 47°C for 
25 min, with temperature and time based on ranges for these parameters that inactivate 
complement in a number of teleosts as summarised by Sakai (1992). Attempts to add 
exogenous barramundi complement to the assay system were not possible due to lack of 
barramundi to supply sufficient quantities of serum. Fish complement is hemolytic as long 
as fish antibodies are used to sensitise red blood cells (Sakai, 1992), this suggests that 
complement from one fish species may be activated by antibody, in complex with antigen, 
from another species via the classical pathway. Therefore, as a substitute, serum from 
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southern bluefin tuna, T. maccoyii, with known complement (C) activity (M. Watts pers 
comm) was added to wells containing I.S. or N.I.S. in 80 RI. volumes, after initial 1 h 
incubation period then incubated for a further 30 min before addition of MTT and 
absorbance measurements taken. Both heat-treated (complement inactivated) and non heat-
treated standards were assayed in triplicate and control wells included those with tuna sera 
in lieu of standard sera and standard immune sera with heat-treated tuna sera. No 
enhancement of inhibitory activity was observed (Table 3.1). In some cases it was possible 
to have negative inhibition i.e. there was apparent growth of bacteria using serum as a 
nutrient, where this occurred the results are expressed as zero inhibition. 
Table 3.1 V. harveyi inhibitory activity of immune (I.S.) and non-immune sera standards 
(N.I.S.) both heat-treated (complement inactivated) and untreated and after the addition of 
tuna sera as a complement (C) source. Values are means ± SE, n = 3. 
Untreated Sera Inhibitory Activity Heat-treated Sera Inhibitory Activity 
Sample (%) Sample (%) 
I.S. + C-source 48.9 ± 5.5 I.S. + C-source 51.4 ± 2.5 
N.I.S. + C-source 0* N.I.S. + C-source -5.0 ± 2.4 (0) 
Tuna sera + C- 
source 
-6.3 ± 1.9 (0) Tune sera + C- 
source 
-10.0 ± 2.7 (0) 
* Used as non-immune standard to determine % inhibitory activity 
To ensure the specificity of the assay for V. harveyi pooled non-immune and pooled immune 
sera were tested for inhibitory activity against Vibrio anguillarum and Yersinia ruckeri. In 
this case all three bacteria were cultured in NB2 broth (NaCl content was not increased to 
1.5% for Y. ruckeri) to densities of approximately 10 8 cells mI.-1 and the assay performed in 
triplicate as described above. The wells containing Y. ruckeri required incubation for 45 min 
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after the addition of MTT to note a substantial difference in OD. Neither non-immune nor 
immune sera displayed any real inhibitory activity toward V. anguillarum or Y. ruckeri 
(Table 3.2) whereas the immune sera had substantial inhibitory activity against V. harveyi 
(73.7%). The inhibitory activity of the pooled immune standard against V. harveyi in the 
specificity assay was higher than that observed for immune sera in the assay assessing the 
effect of complement inactivation (Table 3.1). This discrepancy was probably because the 
pooled immune sera in each assay were not identical and V. harveyi cell numbers were 
lower in the specificity assay. 
For mucus samples, standard non-immune barramundi sera and the antiprotease buffer in 
which mucus samples were stored were also included on each plate. Mucus samples were 
dialysed for at least 72 h against PBS to remove antibacterial components of the antiprotease 
buffer. Additional controls run at the outset of the experiment but not on every plate 
included bacteria and MTT only, medium and MY!' only and serum and MY!' only. 
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Table 3.2 Inhibitory activity of pooled immune sera (I.S.) and pooled non-immune sera 
(N.I.S.) against three bacteria showing the specificity of anti-V. harveyi antisera for V. 
harveyi. Values are means ± SE, n = 3. 
Sera sample 	 Inhibitory activity (%) 
Vibrio harveyi 
	
Vibrio anguillarum 	Yersinia ruckeri 
I.S. 
N.I.S. 
Control (no serum) 
73.7 ±0.4 
0* 
o 
-2.9 ± 4.9 
0* 
o 
(0) 0.1 ±3.5 
0* 
o 
* Used as non-immune standard to determine % inhibitory activity 
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CHAPTER 4 
HUMORAL IMMUNE RESPONSE IN THE SERUM AND MUCUS OF 
BARRAMUNDI AFTER VACCINATION WITH FORMALIN-KILLED Vibrio 
harveyi CELLS VIA IMMERSION AND INTRAPERITONEAL INJECTION AND 
ASSESSMENT OF BACTERIOSTATIC ACTIVITY 
4.1 INTRODUCTION 
It seems accepted that delivery of vaccine by direct immersion falls somewhere between 
intraperitoneal injection and oral administration methods in terms of strength and 
consistency of protection (Palm et al., 1998). Immersion vaccination is, however a 
commonly used administration method in fish culture for protection against bacterial 
pathogens like V. anguillarum (Smith, 1988) and Y. ruckeri (Ellis, 1988a). It is less stressful 
and more economical than individual application of a dose and in some cases has proven to 
be effective, even in the absence of measurable amounts of specific systemic antibody (Croy 
and Amend, 1977). This point is interesting because the protective role of antibody has been 
demonstrated after injection of V. anguillarum bacterin (Thuvander et al., 1987) and passive 
immunisation (Harrell et al., 1975 ). Effectiveness in the absence of specific serum antibody 
suggests that in some cases at least immersion vaccination seems to elicit some form of 
protection other than that of systemic antibody. Whether this equates to local or mucosal 
antibody or the cell-mediated immunity is still not known, although it is well established that 
antibody can be elicited in the mucus (refer Chapter 1). 
An interesting observation is that vaccines delivered by IP injection are the most successful 
in terms of antibody response and protection even though in mammals at least vaccines 
delivered by injection are poor stimulators of mucosal immunity (Brown et al., 1993; 
Hathaway and Kraehenbuhl, 2000). However, mucosally delivered antigens can stimulate 
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systemic antibody. Therefore protection after injection would be at the systemic level 
whereas protection after immersion delivery may well be at the mucosal level. This would 
partly explain why immersion is successful even in the absence of systemic antibody. It 
could also explain differing results from vaccination/ challenge trials where methods of 
challenge vary between immersion, co-habitation and direct injection. Since in fish most, if 
not all, pathogen entry is via the mucosa it seems reasonable to attempt to stimulate this 
immune compartment as an enhancement of the first line of defence. This presumes that fish 
actually possess a separate mucosal immune compartment and there is compelling evidence 
suggesting that this is the case (refer Chapter 1). 
Typically, vaccines against bacterial pathogens are inactivated cultures of the particular 
bacterium. These are relatively simple to produce and are often very effective, though there 
are some notable exceptions (refer Chapter 1). Thus, the aim of this chapter was to 
investigate the immunogenicity in barramundi of a bacterin produced from a formalin-killed 
V. harveyi suspension in order to ascertain its potential as a prototype vaccine. The study 
aimed to quantify the level of antibody elicited in the serum and mucus of barramundi after 
immersion and intraperitoneal injection with the bacterin and to assess any resultant 
antibacterial activity. 
4.2 MATERIALS AND METHODS 
4.2.1 Fish Husbandry 
Barramundi were procured and housed as described in section 3.2. Fish were randomly 
distributed into eight aquaria (12 fish per tank) using a lottery method and acclimated over 6 
weeks. Water quality was monitored every 3-4 days and tanks were cleaned as required with 
50% water exchanges occurring at least every week. Total ammonia levels never exceeded 
0.25 mg L1 and if nitrite levels exceeded 2.0 mg L - ' water exchanges were carried out. 
Before immunisations duplicate aquaria were randomly allocated a treatment using a lottery 
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method, with duplicate tanks for each immunisation method. The fish were weighed at 
commencement of the trial and the mean weight of fish in each treatment group appears in 
Table 4.1. 
Table 4.1 Mean weight (± SE; n = 12) of barramundi per aquaria and treatment group at the 
commencement of the immunisation experiment using V. harveyi bacterin or saline 
delivered by intraperitoneal injection (IP) or irrunersion (IMM) 
Treatment group 	 Replicate aquaria 
1 	 2 
Bacterin 	IP 	 72.6 ± 2.2 	73.0 ± 3.7 
IMM 	 72.5 ± 5.4 	74.8 ± 3.1 
Saline 	IP 	 77.2 ± 3.0 	70.8 ± 4.8 
IMM 	 88.4 ± 6.5 	78.1 ± 5.0 
4.2.2 Bacterin Preparation and Administration 
A formalin-killed broth culture of Vibrio harveyi (strain no. 9056681) was used as a bacterin 
and was prepared as described in section 3.3. In this experiment the bacterin was 
administered to barramundi via immersion and intraperitoneal injection as described in 
section 3.3, however for intraperitoneal injection the bacterin was administered with an 
equal volume of Maintained ® ISA-50 adjuvant. Twenty eight days after the primary 
immunisations, the fish were given an identical secondary dose or booster. 
4.2.3 Sampling Procedures 
At the time of booster immunisation blood samples were taken from individual fish via 
caudal puncture Fourteen days later all fish were lethally anaesthetised and blood, skin 
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mucus and gut mucus samples were taken as outlined in section 3.4. In this experiment skin 
mucus was sampled by gently scrapping the skin from the operculum to the caudal peduncle 
with the back of a scalpel blade and immediately placed in 1.5 mL tubes containing 0.5 mL 
of borate buffer with protease inhibitors (section 3.4) on ice. Blood was collected by caudal 
puncture or after severing the tail, allowed to clot at room temperature for several hours then 
kept at 4°C until serum was drawn off and stored at -20°C until assayed. 
4.2.4 SDS-PAGE and immunoblotting 
Western blots were performed to detect Ig in mucus samples. These samples were prepared 
by lyophilising for 48 h, reconstituing in 400 1iL and 200 1.1.L of sterile distilled water for the 
gut and skin mucus samples respectively and finally by centrifugation at 8800 x g for 5 min 
in a microcentifuge. Supernatants were heated (100°C for 4 min) in reducing buffer as 
previously described in section 2.2.2 and electrophoresed on 10% polyacrylamide gels at 
200 v and 60 mA for 1 hour. Proteins were then electrotransferred from the polyacrylamide 
gels to nitrocellulose membranse as described in section 2.2.4 at 60 V and 200 mA for 55 
min. Standard barramundi anti-V. harveyi (strain no. 9056681) serum was included as a 
control on all gels. Membranes were then probed following the protocol previously 
described (section 2.2.5) using rabbit anti-barramundi Ig (HC2) diluted 1:100 in 1% 
skimmed milk as the primary antibody. 
4.2.5 Enzyme-linked immunosorbent assay (ELISA) 
A standard indirect ELISA protocol using buffers and equipment as described in section 
2.2.7 was followed to detect specific antibody in barramundi serum and mucus samples. 
Optimal dilutions of coating antigen (V. harveyi killed-whole cells; strain no. 9056681) and 
rabbit anti-barramundi Ig antiserum as secondary antibody (SpA-purified MBP 3) were 
determined firstly by doing a typical chessboard titrations (Crowther, 1995). Rabbit anti-
barramundi Ig antiserum (starting at 1:200) was titrated against barramundi Ig (SpA-
purified, starting at 10 pg mL 1 protein). The SpA-purified MBP 3 anti-barramundi Ig 
antiserum was used as it was the most appropriate in terms of titer and specificity (antiserum 
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designated HC 2 had not been produced at this time). Once a suitable working dilution 
(1:400) was determined for the rabbit anti-barramundi Ig antiserum, standard barramundi 
anti-V.harveyi antiserum (starting at 1:10) was titrated against whole V. harveyi cells (strain 
no. 9056681; starting at 220 [ig bacterial cells m.1_, - ` wet weight) in a second chessboard 
titration. Optimal antigen concentration of 18 pg m1: I was chosen and this was used for 
subsequent processing of samples from this experiment. Optimal antigen concentration is 
defined as the least amount giving a significant OD reading (Arkoosh and Kaattari, 1992), in 
this case the highest OD within the linear portion of the titration curve. The standard anti-V. 
harveyi antiserum (immune standard) was titrated in duplicate against bacterial cell antigen 
to calculate a serum volume equating to 1 unit of antibody activity. Specific antibody 
activities of samples, expressed as units of antibody activity per volume of serum, were 
determined relative to the positive standard included on all plates and calculated as follows: 
activity of sample = activity of standard x 50% volume of standard/ 50% volume of 
sample 
where activity of standard is the reciprocal volume of the standard anti-V harveyi antiserum 
which gives 50% maximum OD, as determined from a titration curve, and is assumed to 
contain 1 unit of activity (Arkoosh and Kaatari, 1990). The activity of the standard is a 
constant in the equation, determined from its full titration, whereas the other terms are 
derived from individual plates and thus account for variations between plates. All samples 
and standards, both immune and non-immune, were titrated in duplicate from dilutions of 
1:100 to 1:1600. Samples which displayed a maximum OD that was less than 50% of the 
maximum OD of the immune standard were designated as having no anti-V. harveyi activity. 
4.2.6 Bacteriostatic assay 
Bacterial inhibitory activity of sera and mucus were assayed as described in section 3.5.5. 
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4.2.7 Statistical analyses 
Data were analysed with a one-way analysis of variance (ANOVA) using JMP 3.2.1 
statistical package. ANOVA assumptions of data normality and homogeneity of variance 
were tested using the Shapiro-Wilk W test and Bartlett's test respectively. Nested analyses 
were used to find differences in replicate aquaria within treatment groups for specific anti-V. 
harveyi antibody activity and bacterial inhibitory activity. Differences were highlighted as a 
multiple comparison of means was carried out (Tukey-Kramer HSD test). Serum V. harveyi 
bacterial inhibitory data failed to fulfill assumptions of normality and homogeneity of 
variances both before and after common logarithmic transformation, therefore a non-
parametric test (Kruskal-Wallis test) was used for statistical analysis. Antibody activities 
within treatment groups after primary and secondary immunisations were compared using a 
t test for paired comparisons. A common logarithmic transformation was applied to these 
data to comply with the data normality and homogeneity of variance assumptions. 
Correlation coefficients were determined and tested for significance (Sokal and Rohlf, 1987) 
when looking at associations between specific antibody activity and bacterial inhibitory 
activity. For all tests a significance level of P < 0.05 was adopted. 
4.3 RESULTS 
4.3.1 SDS-PAGE and immunoblotting 
Electrophoretic profiles of the skin and gut mucus revealed a number of bands within the 97 
and 31 lcDa size range (Figure 4.1) however, western blotting detected no strong bands of 
corresponding MW to either LC or HC Ig in any mucus samples that were representative of 
all immunised groups of fish (Figure 4.2). Anti-barramundi LC and HC Ig antisera both 
showed bands corresponding to LC and HC components in the control serum but only HC 2 
showed faint bands in mucus samples corresponding to the MW of HC Ig (Figure 4.2A). 
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4.3.2 ELISA optimisation 
The optimal dilution of the rabbit anti-barramundi antiserum (MBP 3) chosen was 1:400 as 
determined from the chequerboard titration of the antiserum against the protein A-purified 
barramundi Ig (Figure 4.3). A strong signal (OD 492 nm of 1.5) is recorded at this dilution, 
although a 1:200 did increase the OD and was sufficient to eliminate background staining in 
a Western blot (see section 2.3.3), 1:400 was considered more appropriate for the more 
sensitive ELISA. The chequerboard titration of barramundi anti-V. harveyi standard 
antiserum against whole V. harveyi cells (Figure 4.4) indicated that optimal V. harveyi 
antigen concentration was approximately 18 jig mL - I wet weight. This concentration of 
antigen gave OD readings greater than 1.5 at all the antisera dilutions. The titration of the 
standard anti-V. harveyi antiserum and subsequent regression of the linear portion of the 
curve (Figure 4.5A & B) showed that 50% of the maximum OD of the standard was 0.520. 
The volume of the serum standard giving this OD was calculated as 4.1 x 10 -3 [EL from the 
equation of the straight line portion of the curve. Therefore the activity of the serum 
standard is 243 units gL-1 . 
4.3.4 Specific anti-V. harveyi antibody activity and bacterial inhibitory activity 
Specific antibody activity was detected in both IP and IMM bacterin-immunised groups of 
barramundi after both primary and secondary immunisations (Figures 4.6 & 4.7). There was 
some activity noted in control groups 28 days after primary immunisations (Figure 4.6) but 
this was limited to 4 individuals. No differences were detected between aquaria within 
treatments after either primary or secondary treatments (P = 0.35 & P = 0.25), thus the data 
were pooled at this level. The antibody response was significantly higher in the IP-treated 
group after each immunisation (P = 0.01 & P < 0.0001) and possible evidence of an 
anamnestic response was seen as significantly higher levels of antibody activity were 
recorded after the secondary immunisation (P = 0.0025) (Figure 4.8). There was no 
concomitant increase in antibody activity noted in the IMM-treated group. The ELISA found 
no anti-V.harveyi activity in any of the mucus samples. 
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As with the specific antibody levels serum bacteriostatic activity was significantly higher in 
IP-bacterin treated fish (P < 0.001) (Figure 4.9). There was also activity noted in sera from 5 
individuals from control groups, although these were not the same fish that demonstrated 
antibody activity. Examination of the relationship between serum antibody levels and 
bacteriostatic activity revealed no statistical correlation between these parameters (Figures 
4.10 & 4.11). 
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Figure 4.1 Electrophoretic profiles of skin mucus and gut washings from barramundi 
subjected to SDS-PAGE in 10% gel under reducing conditions. A. Barramundi serum 
(lane 1) and skin mucus (lanes 2 & 3). B. Gut washings (lanes 1 & 2). Both gels were 
silver stained. 
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Figure 4.2 Immunoblots of skin and gut mucus from barramundi . A. Probed with HC 
2 at 1:100; skin mucus (lanes 1-4), barramundi serum with heavy chain Ig (HC) 
labelled (lane 5) and gut mucus (lane 6) B. Probed with LC 1 at 1:100; gut mucus 
(lanes 1 & 2), barramundi serum with light chain Ig (LC) labelled (lane 3) and skin 
mucus (lanes 4-6). 
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Figure 4.3 Chequerboard titration of rabbit anti-barramundi Ig antiserum (SpA-purified 
MBP 3) serially diluted from 1:200 to 1:1600 against SpA-purified barramundi Ig serially 
diluted from 20 to 0.02 pg protein. 
V. harveyi whole cell concentration (pg mL -I wet weight) 
Figure 4.4 Titration of V. harveyi whole cell antigen against various dilutions of 
barramundi anti-V. harveyi standard antiserum indicating an optimal antigen concentration 
of 18 pg mL-1 (wet weight). 
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Figure 4.5 Titration curve and linear regression of barramundi anti-V. harveyi (strain no. 
9056681) antiserum. A. Antiserum titrated through dilution series of 1:20 to 1:40960 
against V. harveyi (strain no. 9056681) whole cell antigen coated at 18 jig mL -I (wet 
weight). B. Regression of linear portion of curve (r 2 = 0.929) showing the volume of 
serum giving 50% of the maximum OD from which a unit of antibody activity is 
derived. 
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Figure 4.6 Specific anti-V. harveyi activity of barramundi serum 28 days after primary 
immunisation with V. harveyi bacterin or saline via intraperitoneal injection (IP) with 
Montanide® ISA-50 adjuvant, or immersion (IMM). A. Individual fish within 2 aquaria 
per treatment group. B. Fish per treatment group, values are means + SE and disparate 
superscripts show significant differences (P = 0.01, Tukey-Kramer HSD test). 81 
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Figure 4.7 Specific anti-V. harveyi activity of barramundi serum 14 days after secondary 
immunisation with V. harveyi bacterin via intraperoitoneal injection (IP) with Montanide® 
ISA-50 adjuvant, or immersion (IMM). A. Individual fish within 2 aquaria per treatment 
group. B. Fish per treatment group, values are means + SE and saline treated controls 
showed no antibody activity. Disparate superscripts show significant differences (P < 
0.0001, Tukey-Kramer HSD test). 
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Figure 4.8 Specific anti-V. harveyi antibody activity of barramundi serum immunised 
with V. harveyi bacterin (bact) via intraperitoneal injection (IP) with Montanide ® ISA-50 
adjuvant, or immersion (IMM) after primary and secondary immunisations. Values are 
means + SE, and disparate superscripts significant differences within a treatment (P = 
0.003, paired t Test ). 
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Figure 4.9 Serum bacteriostatic activity of barramundi after immunisation with V. 
harveyi bacterin via intraperitoneal injection (IP) with Montanide ® ISA-50 adjuvant and 
immersion (IMM) 14 days after secondary immunisations. A. Individual fish within 2 
aquaria per treatment group of bacterin (bact) or saline control (con). B. Activity of fish 
sera from bacterin treated groups only, values are means + SE and disparate superscripts 
show significant differences (P < 0.001, Kruskal-Wallis Test) 
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Figure 4.10 Relationship between anti-V. harveyi antibody activity and bacteriostatic 
activity of serum from barramundi immunised with V. harveyi bacterin administered by 
intraperitoneal injection with Montanide®  ISA-50 adjuvant or immersion and including 
individuals from saline treated control groups displaying bacteriostatic and/or anti- V. 
harveyi antibody activity (r = 0.234, n = 31). 
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Figure 4.11 Relationship between barramundi serum anti-V. harveyi antibody 
activity and serum bacteriostatic activity showing no significant correlation (P > 
0.05) when examined by individual treatment group. A. Bacterin administered by 
intraperitoneal injection with Montanide ® ISA-50 adjuvant ( r = 0.218, n = 14). B. 
Bacterin administered by immersion ( r = 0.472, n = 11). 
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4.4 DISCUSSION 
A formalin-killed V. harveyi whole cell preparation will be useful as a prototype vaccine for 
barramundi. All bacterin-immunised fish produced systemic antibody to V. harveyi whole 
cells with IP injected barramundi displaying substantially higher (a ten-fold increase) 
antigen-specific antibody activity compared to the IMM group. In addition, there was 
approximately a three-fold increase in antibody activity 14 days after a secondary IP 
injection. Both increases in specific antibody activity were statistically significant. 
These findings raise two points. First, the comparatively lower humoral response after 
immersion bacterin delivery and, second the indication of an anamnestic response after IP 
injection but not immersion. The relatively lower response of the IMM group concurs with 
much of the literature describing little or no systemic humoral responses in fish after 
immersion immunisation (e.g. Baba et al., 1988; Thorburn and Jansson, 1988; Nakanishi 
and Otoake, 1997) and when comparing responses to IP and IMM delivered antigen (e.g. 
Whittington et al., 1994; Thune et al., 1997). However, some studies report elicitation of 
specific antibody of a similar magnitude after secondary immunisations when comparing 
antigen administration methods (Palm et al., 1998). Differences probably relate to the type 
of antigen and its ability to be transported and exposed to the systemic immune system. The 
magnitude of the immune response depends, among other factors, on antigen concentration 
and its physical nature i.e if it is particulate or soluble (Nakanishi and Ototake, 1997). 
During exposure by immersion the main route of antigen uptake is variously attributed to the 
skin (Ototake et al., 1996), gills (Bowers and Alexander, 1981; Smith, 1982; Zapata et al., 
1987), and via the intestinal tract after ingestion (Robohm, 1986; Robohm and Koch, 1995). 
Tatner (1987) found significant amounts of radiolabeled A. salmonicida in the gut of 
rainbow trout administered by bath but could not conclude that that this site was totally 
responsible for the induced immunity. In the studies referred to above measuring responses 
after immersion and/or IP injection different antigens and fish species were used which 
could explain the disparity of the results. In the present experiment the lower response after 
immersion immunisation may have been due to less antigen uptake relative to IP injection 
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and thus a lower antibody response. Whether or not the differences observed in humoral 
responses after each administration method parallel differences in protection is not known 
given the lack of vaccination/challenge data. It is clear that immersion immunisation 
stimulates several immune mechanisms, both cell-mediated and humoral, which contribute 
to disease prevention (Nakanishi and Ototake., 1997) but many aspects of immersion 
immunisation remain controversial. For example, the type of immunity induced, the 
relationship between systemic antibody and protection and, the major route of antigen 
uptake after immersion antigen delivery are all uncertain. 
Regarding the indication of an anamnestic response, in this study IP-injected fish received 
the bacterin with an oil-based adjuvant which may result in a magnified antibody response. 
In the context of the aim of the study an adjuvant was used in the IP administration to ensure 
a detectable response. However, observations of a heightened antibody response after 
secondary IP immunisation may be indicative of memory induction or, may equally be due 
to the adjuvant. The adjuvant used was Montanide ® ISA-50 which is classified as an 
immunostimulatory oil emulsion (Leenaars et al., 1999) and would have acted as an antigen 
reservoir and effectively prolonged retention of the antigen. Subsequent studies where 
bacterin is administered without adjuvant have been carried out and are reported later in this 
thesis. 
The bacterial inhibitory activity of the serum from both bacterin-treated groups of fish 
highlights the potential of the bacterin as a vaccine. This activity was highest in IP-
immunised fish which was six times greater than in IMM-immunised fish. Although there 
was no apparent correlation between antibody activity and bacteriostatic activity, the IP-
treated group showed consistently higher levels for both activities. 
The lack of detection of antigen-specific or any antibody in mucus samples from any 
treatment group by either ELISA or Western blot may mean that either there was no 
antibody in mucus samples, mucosal Ig is sufficiently different to be less reactive with anti-
barramundi serum Ig reagents, or detection techniques used in this study are not sensitive 
enough. Lack of detectable Ig in the skin mucus was surprising given that Ig does exist in 
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fish mucus and has been shown to be inducible in cutaneous mucus of teleosts after 
immersion immunisation (Lobb, 1987), IP injection (Ourth, 1980; St. Louis-Cormier et al., 
1984) and enteric antigen delivery (Rombout et al., 1986; Rombout et al., 1989; Wong et 
al., 1992; Jenkins et al., 1994; Cain et al., 2000). It is therefore unlikely that no Ig was 
present in the cutaneous mucus of barramundi. Though Rombout et al. (1993) demonstrated 
differences between mucus and serum Ig in carp, C. carpio, via differential recognition with 
mAbs, polyclonal antisera were used in this study. Such antisera would be expected to be 
reactive with both forms of Ig, given they are a heterogeneous mixture of antibodies reactive 
with numerous epitopes on an Ig molecule. It therefore seems likely that antibody was 
present in the skin mucus of barramundi but at levels too low to detect using current 
methods. Thus, it cannot be ascertained from this experiment whether or not immersion 
immunisation with a bacterin elicits an antibody response from the mucosa. 
The apparent lack of Ig in the gut mucus may similarly indicate levels too low to detect or, 
that no antigen reached the gut-associated lymphoid tissue (GALT), which in teleosts are not 
of the organised nature as found in mammals (Press and Evensen, 1999). Though it is 
reasonable to assume that during immersion some antigen would be ingested and have an 
opportunity to reach the gut, Ototake et al. (1996) proposed that after immersion vaccination 
the skin is the predominant site of antigen uptake and in their study little or no antigen was 
found in the intestine. Therefore, in this study it is possible that no bacterin reached the 
intestine, at least in an immunogenic form. A number of studies have reported antigen 
uptake in the intestine (e.g. Rombout et al., 1986; Joosten et al., 1995; Joosten et al., 1996) 
though in most cases antigen was delivered via the oral or anal route and not by immersion. 
Another possibility for the failure to detect Ig in the gut washings is that any antibody 
secreted into the gut mucus was transient. In mammals, the majority of locally produced and 
secreted Ig at the mucosal surfaces is IgA (McGhee et al., 1992), an isotype resistant to 
proteolytic degradation. Fish lack secretory Ig analogous to IgA in mammals (Ellis, 1999) 
and consequently fish Ig may be subject to proteolytic attack on secretion into the gut 
environment. 
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CHAPTER 5 
COMPARISON OF INTRAPERITONEAL INJECTION, ANAL INTUBATION AND 
IMMERSION AS BACTERIN ADMINISTRATION TECHNIQUES FOR 
BARRAMUNDI 
5.1 INTRODUCTION 
One area of research in fish vaccinology involves administration methods in an effort to 
identify those that are most economic, impose the least stress and stimulate the appropriate 
immune response. There are basically three methods of delivering antigens to fish to 
stimulate the immune systems and confer protection against infectious disease; by injection, 
immersion in an antigen suspension or, perorally. Each has advantages and disadvantages in 
terms of economics, stress and efficacy. Injection requires individual handling and 
anaesthesia and often the use of adjuvant, but delivers a precise amount of antigen and is 
usually the most effective (Ellis, 1988b) and, in some cases, is the only effective 
administration method e.g. for furunculosis when an adjuvant is required (Newman, 1993; 
Press and Lillehaug, 1995). Immersion is less stressful than injection as it requires no 
individual manipulation, however, it is less precise and may require greater volumes of 
vaccine when larger fish are being immunised. Immersion exposure to antigen does parallel 
the natural entry route of pathogens (Moore et al., 1998), is practical for mass vaccination 
and, is currently the delivery method used for many commercial vaccines (Nalcanishi and 
Ototake, 1997). Immersion vaccine delivery has a variable success rate for a number of 
bacterial diseases but it is quite effective against diseases caused by V. anguillarum and V. 
ordalii (Newman, 1993). Peroral antigen delivery, where vaccine is incorporated into food, 
is the least stressful, requires no individual handling or group moving but it is also the least 
successful to date compared to immersion and injection (Rombout et al., 1986; Lillehaug, 
1989b; Dec et al., 1990) and, it is difficult to ensure that each individual receives an 
90 
effective dose. Nevertheless, peroral delivery is often seen as the most desirable means of 
vaccine delivery because of its advantages. Vaccination of fish by immersion and perorally 
have the potential to stimulate mucosal immunity which, as mentioned in Chapter 1, has 
some autonomous function and may be the preferred site of immune induction given that 
many pathogens initiate infections at these sites (McGhee et al., 1992). 
Desirability to develop oral vaccines has led to investigation of antigen uptake in the gut and 
exposure to cells of the gut-associated lymphoid tissue (GALT) and this is often achieved by 
peranal administration of antigen. The priority being to ascertain whether the antigen can be 
presented to lymphoid cells via the gut, then if successful, means of delivering the antigen to 
the gut perorally can be explored. The lack of success of oral vaccine delivery is often 
attributed to antigen degradation in the acidic environment of the stomach before it reaches 
responsive areas in the hind gut (Johnson and Amend, 1983; Rombout et al., 1986; 
Lillehaug, 1989a). Substantial efforts have been employed to find means of protecting 
antigens from gastric and pancreatic secretions, including various forms of encapsulation 
(Joosten, et al., 1995; O'Donnell et al., 1996; Azad et al., 1999) and coating with pH 
sensitive polymers (Piganelli et al., 1994). Results from these efforts have been promising in 
terms of antigen uptake, serum antibody titers and survival after challenge. 
This study attempted to compare immune responses in barramundi to V. harveyi bacterin 
administered via various routes. The immune systems of barramundi have not been 
extensively studied, therefore information on how this species responds to different vaccine 
administration techniques will be valuable. To that end the aim of this experiment was to 
investigate both the specific humoral response and non-specific immune parameters after 
administration of a V. harveyi bacterin via intraperitoneal injection, immersion and anal 
intubation, the latter method to ensure vaccine delivery to the gut-associated lymphoid 
tissue. A priority was to confirm the ability of barramundi to mount a systemic and/or 
mucosal antibody response after peranal bacterin delivery. This study differs from the 
previous one described in Chapter 4 in that no adjuvant was used for any bacterin 
administration method and a more pathogenic strain of the bacterium was used. This strain 
was used as it has been identified as more pathogenic subsequent to the experiment detailed 
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in Chapter 4 and because the strain was to be used as a prototype vaccine in commercial 
trials. 
5.2 MATERIALS AND METHODS 
5.2.1 Fish Husbandry 
Barramundi were procured and housed as described previously in section 3.2 and were 
acclimated over 4 weeks. Due to the large numbers of aquaria used for this trial commercial 
heaters were installed to maintain uniform temperatures in all aquaria (mean temperature 
was 26.5°C ± 0.3). Prior to commencement of the trial duplicate aquaria, each containing 10 
fish, were randomly allocated a treatment using a lottery method and fish were similarly 
randomly allocated to aquaria. The fish were weighed at the commencement of the trial and 
the mean weight of fish in each treatment group appears in Table 5.1. 
5.2.2 Bacterin preparation and administration 
The bacterin was prepared from V. harveyi strain no. 9050405 as previously described for 
strain no. 9056681 in section 3.3. Bacterin administration methods were intraperitoneal 
injection (IP), immersion (IMM) and anal intubation (Al) to facilitate delivery to the GALT 
and were carried out as described in section 3.3. Actual doses were 200 pl. of vaccine 
(approximately 0.08 mg cells wet weight per gram of fish) for IP injection, a 60 s dip in 1:5 
dilution of the bacterin containing approximately 2 x 10 7 cells mL- I for IMM and, 300 pi, of 
vaccine (approximately 0.12 mg cells wet weight per gram of fish) for AI. Placebos, 
consisting of seawater for the immersion and saline with 0.5% formalin for the intubation 
and intraperitoneal injection, were administered to fish using the same methods. In addition 
to these treatment groups a control group remained naive to all treatments and handling. All 
fish were bled and re-immunised as above after 21 days. 
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Table 5.1 Mean weight (± SE; n = 10) of barramundi per aquaria and treatment group at the 
commencement of the immunisation experiment using V. harveyi bacterin or saline 
delivered by intraperitoneal injection (IP), immersion (IMM) and anal intubation (Al) 
Treatment group 	 Mean weight (g) in replicate aquaria 
1 	 2 
Bacterin 
Saline 
IP 	 98.3 ± 7.6 	104.5 ± 5.9 
IMM 	 89.1 ± 4.2 	88.3 ± 3.6 
Al 	 95.0 ± 4.9 	98.9 ± 3.7 
IP 	 95.6 ± 5.4 	99.8 ± 4.1 
IMM 	 94.2 ± 3.0 	92.9 ± 4.5 
Al 	 100.2 ± 8.3 	83.3 ± 2.9 
5.2.3 Sampling Procedures 
Prior to sampling all fish were starved for 48 h. Ten days post booster five fish from each 
aquarium were lethally anaesthetised, sampled for blood, mucus (skin and gut) and head 
kidney. Blood was collected by caudal puncture, allowed to clot then stored at 4°C overnight 
before serum was removed and frozen at -20°C. Skin mucus samples were collected using a 
cane skewer as described in section 3.4, similarly, gut mucus and head kidney tissue were 
collected as previously detailed in sections 3.4 and 3.5.1 respectively. The remaining five 
fish from each aquarium were similarly processed 21 days post booster. Sampling periods 
after booster of 10 and 21 days were chosen so as to reflect a reasonable time frame in 
which to detect differences in the parameters to be measured. The time frame was based on 
previous reports for detection of responses after booster vaccination (Ainsworth et al., 1995; 
Joosten et al., 1996; Palm et al., 1998). 
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5.2.4 Immune assays 
Macrophage isolation from head kidney tissue and estimation of phagocytic indices of this 
cell suspension were carried out according to procedures detailed in sections 3.5.1 and 3.5.2. 
Assays to measure serum lysozyme, anti-V. harveyi antibody activity by ELISA and 
bacteriostatic ability were performed on sera and mucus samples using protocols previously 
detailed (sections 3.5.3 - 3.5.5). 
The ELISA was performed using sonicated V. harveyi (strain no. 9050405) cells as the 
coating antigen. This differs from whole cell coating of strain no. 9056681 used for ELISA 
described in Chapter 4 as whole cells of strain no. 9050405 failed to adhere uniformly to 
plates. An additional modification to the ELISA used in Chapter 4 was the use of a different 
anti-barramundi Ig antiserum (HC 2) as secondary antibody which was subsequently found 
to be more specific. Recalibration of the assay found an optimal working concentrations of 
1:400 dilution for HC 2 and antigen coating concentration of 5.5 lig mL-I protein for the 
bacterial sonicate (Figure 5.1 & 5.2). The strain difference also required production of 
pooled barramundi anti-V harveyi antisera for use as a positive standard to be used on all 
plates. This was produced by immunising six fish by IP injection with 0.08 mg (wet weight) 
bacterin per gram of fish with an equal volume of Montanide ® ISA-50 adjuvant, re-
immunising after 4 weeks, then harvesting serum after a further 2 weeks. The sera were then 
pooled and titrated in duplicate against the bacterial sonicate (Figure 5.3A) and linear 
regression used to calculate the volume of sera equating to 1 unit of antibody activity. As 
detailed in section 4.2.5 the specific antibody activities of samples are expressed as units of 
antibody activity per volume of serum, although in this case the activity of the standard was 
the reciprocal volume of the pooled sera which yielded 40% of the maximum OD. The 
volume of sera giving 40% of the maximum OD was 8.3 x 10 RI, therefore the activity of 
the sera standard is 120 units pL- I. This differs to the 50% maximum OD used for 
calculations in the experiment reported in Chapter 4 because there was a greater difference 
between the activities of the samples and the standard antisera. All samples and standards 
were titrated from dilutions of 1:50 to 1:3200. 
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Figure 5.1 Chequerboard titration of rabbit anti-barramundi Ig antiserum (HC 2) serially 
diluted from 1:200 to 1:1600 against SpA-purified barramundi Ig serially diluted from 10 to 
0.08 pg mL-1 protein. 
O
pt
ic
al
 d
en
si
ty
  (4
92
 n
m
)  1.2 
1 
0.8 
0.6 
0.4 
0.2 
0 
—13— 1 in 10 
—A-1 in 40 
—o— 1 in 160 
68.8 34.4 	17.2 	8.6 	4.3 	2.15 1.07 0.54 0.27 
V. harveyi sonicate concentration (pg mL -1 protein) 
Figure 5.2 Titration of V. harveyi sonicate (strain no. 9050405) against various dilutions of 
barramundi anti-V.harveyi (strain no. 9050405) standard pooled antisera indicating an 
optimal protein concentration of approximately 5.5 pg mL -1 . 
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Figure 5.3 Titration curve and linear regression of barramundi anti-V. harveyi (strain no. 
9050405) pooled antisera. A. Antisera titrated through dilution series 1:5 to 1:10240 against 
V. harveyi sonicate (strain no. 9050405) coated at 5.5pg m1: 1 (protein). B. Regression of 
linear portion of curve (r 2 = 0.983) showing the volume of sera giving 40% of the maximum 
optical density from which a unit of antibody activity is derived. 
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5.2.5 Statistical analyses 
All data were analysed with a one-way analysis of variance (ANOVA) using the JMP 3.2.1 
statistical package. ANOVA assumptions of data normality and homogeneity of variances 
were tested using the Shapiro-Wilk W test and Bartlett's test respectively. Nested analyses 
were used to ascertain differences in replicate aquaria within treatments and due to time (i.e. 
sampling times of 10 and 21 days post booster), thus factors of aquaria and time were nested 
within treatment for analyses. Significant differences between treatment groups were 
highlighted using multiple comparisons of means (Tukey-Kramer HSD test). Phagocytic 
index data were not normally distributed which a common logarithmic transformation failed 
to rectify (P = 0.046), therefore a non-parametric test (Kruskal-Wallis test) was applied. 
Similarly, serum V. harveyi inhibitory activity data, due to a large number of zero values, 
fulfilled neither assumptions of normality nor homogeneity of variances, thus the same non-
parametric test was used. Antibody activities between treatment groups and after primary 
and secondary immunisations were compared using a t test for paired comparisons. In 
examining associations between specific antibody activity and V. harveyi inhibitory activity 
correlation coefficients were determined and tested for significance (Sokal and Rohlf, 1987). 
When examining differences in all parameters between aquaria or treatment groups at 10 
and 21 days post booster, data were pooled if analyses had P values > 0.1. For all tests a 
significance level of P < 0.05 was adopted. 
5.3 RESULTS 
Specific humoral responses were noted in all bacterin-immunised groups after both primary 
and secondary immunisations (Figures 5.4 & 5.5). In both instances some anti-V. harveyi 
activity was noted in control (saline-immunised) fish, however this activity was only found 
in five individual fish after both primary and secondary immunisations (Figures 5.4A and 
5.5A). There was no difference in antibody activity between tanks within treatment groups 
(P = 0.35) or at 10 and 21 days after secondary immunisations (P = 0.19), thus data were 
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pooled. Analyses of antibody activity between groups 21 days after primary immunisation 
showed that only the IP bacterin-immunised group was significantly higher than its saline-
treated control. However, there was no significant difference between IMM and Al bacterin-
immunised groups and their controls, although there was a trend for higher antibody activity 
in the bacterin-treated groups. A similar pattern occurred 21 days after secondary 
immunisation however, for the bacterin-immunised fish antibody activity was significantly 
higher in the IP group compared to IMM and Al groups (P < 0.001). Antigen specific 
antibody activity was more consistent in the bacterin treated groups with the majority of fish 
responding whereas control groups had a small percentage of responders (Table 5.2). 
Table 5.2 Number of individual barramundi displaying anti-V. harveyi antibody activity, as 
determined by ELISA, in serum after primary and secondary immunisations with V. harveyi 
bacterin or saline via intraperitoneal injection (IP), immersion (IMM) or anal intubation (Al) 
Treatment 	Administration method 	Number of individual fish displaying anti-V. 
harveyi antibody activity: 
10 immunisation 2° immunisation 
Bacterin IP 18/20 (90%) 20/20 (100%) 
IMM 5/18 (27%) 8/20 (40%) 
Al 7/20 (35% 8/20 (40% 
Saline IP 1/19 (5%) 1/20 (5%) 
IMM 0/20 (0) 1/20 (5%) 
Al 4/20 (20%) 1/20 (5%) 
Naive n.a. 2/20 (10%) 
n.a. not applicable as naïve group were only sampled at the end of the experiment 
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The increase in antibody activity observed in the IP group after the secondary immunisation 
(Figure 5.6) was significantly higher than activity noted after the primary immunisation (P < 
0.001), which may be indicative of memory induction. Similar comparisons in the IMM (P = 
0.22) and Al (P = 0.48) groups showed no significant increase in antibody activity after 
secondary immunisations. 
Bacteriostatic activity of barramundi serum, expressed as percentage inhibition of V. harveyi 
relative to pooled non-immune standard barramundi sera, was observed in all bacterin-
immunised groups as well as in sera of some individuals in control groups (Figure 5.7A & 
B). This activity was however, significantly higher and less variable in the IP bacterin group 
(P < 0.001) with all individuals displaying substantial inhibition of V. harveyi and 16 of 18 
fish recording greater than 60%. Inhibitory activity was generally much lower and more 
varied in other groups with 50% or less (Table 5.3) of individuals showing V. harveyi 
inhibitory activity as assessed by this assay. There was no significant difference within 
groups at 10 and 21 days post booster (P = 0.25), therefore data were pooled. 
Examination of the relationship between serum anti-V. harveyi antibody activity and 
inhibitory activity found no correlation (Figures 5.8 and 5.9) However, sera from IP-
immunised fish was consistently high in bacterial inhibitory activity and had variable 
specific antibody activity whereas sera from immersed and anally intubated displayed 
activity for both parameters in only some of the fish sampled. Analyses of all mucus 
samples taken from the hind gut and the skin failed to show either specific antibody activity 
or V. harveyi inhibitory activity. 
There was no real trend evident in the non-specific parameters examined with no difference 
in serum lysozyme activity between any treatment groups (P = 0.93) (Figure 5.10A). 
Although phagocytic indices of anterior kidney macrophage suspensions showed some 
statistically significant differences (Figure 5.10B), there was no enhancement of this 
parameter between treatment groups. 
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Table 5.3 Number of individual barramundi displaying V. harveyi inhibitory activity in 
serum after immunisation with V. harveyi bacterin or saline via intraperitoneal injection (IP), 
immersion (IMM) or anal intubation (AI) 
Treatment Administration method Number of individual fish displaying V. 
harveyi inhibitory activity 
Bacterin IP 18/18 (100%) 
IMM 9/18 (50%) 
Al 6/15 (40%) 
Saline IP 5/14 (35%) 
IMM 6/14 (42%) 
Al 7/18 (38%) 
Naive 3/9 (30%) 
No enhancement of non-specific immune parameters were noted in this experiment. 
Phagocytic indices (Figure 5.10A) of head kidney macrophage suspensions indicated no 
macrophage activation between fish immunised via various methods with either bacterin or 
saline. In some cases, phagocytic indices were significantly lower (P < 0.001) 21 days post 
secondary immunisations in Al (both bacterin and saline) and naive fish than in IP and IMM 
fish. Similarly serum lysozyme activity (Figure 5.10B) showed no significant enhancement 
(P = 0.13) between or within treatment groups at 10 and 21 after secondary immunisations 
(P = 0.12). 
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Figure 5.4 Specific anti-V. harveyi antibody activity of barramundi serum 21 days after 
primary immunisation with V. harveyi bacterin or saline via intraperitoneal injection (IP), 
immersion (IMM) or anal intubation (Al). A. Individual fish within 2 aquaria per treatment 
group of bacterin (bact) or saline control (con). B. Fish per treatment group, values are 
means + SE and disparate superscripts show significant differences (P = 0.016, Tukey-
Kramer HSD test) * IMM control group displayed no activity. 
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Figure 5.5 Specific anti-V. harveyi antibody activity of barramundi serum after booster 
immunisation with V. harveyi bacterin or saline via intraperitoneal injection (IP), immersion 
(IMM), anal intubation (Al) or naive to immunisation and handling. As no difference was 
detected between sampling periods of 10 and 21 days data were pooled. A. Individual fish 
within 2 aquaria per treatment group of bacterin (bact) or saline control (con). B. Fish per 
treatment group. Values are means + SE and disparate superscripts show significant 
differences (P < 0.001, Tukey-Kramer HSD test, n = 20). 
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Figure 5.6 Specific anti-V. harveyi antibody activity of barramundi serum immunised with 
V. harveyi bacterin (bact) via intraperitoneal injection (IP), immersion (IMM) and anal 
intubation (AI) after primary and secondary immunisations. Values are means + SE, and 
disparate superscripts show significant differences (P < 0.001, paired t Test). 
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Figure 5.7 V. harveyi inhibitory activity of barramundi serum (relative to pooled non-
immune standard sera) after immunisation with V. harveyi bacterin via intraperitoneal 
injection (IP), immersion (IMM) and anal intubation (Al) 21 days after secondary 
immunisations. Data were pooled as there was no difference between 10 and 21 days 
post booster A. Individual fish within 2 aquaria per treatment group of bacterin (bact) or 
saline control (con). B. Fish per treatment group, values are means + SE and disparate 
superscripts show significant differences (P < 0.001, Kruskal-Wallis test ). 104 
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Figure 5.8 Relationship between barramundi serum anti-V. harveyi antibody activity 
and serum V. harveyi inhibitory activity (relative to pooled non-immune standard 
sera) showing no significant correlation (P > 0.05) when examined by individual 
treatment group. A. Bacterin administered by intraperitoneal injection ( r = 0.041, n 
= 18). B. Bacterin administered by immersion ( r = 0.334, n = 12). 
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Figure 5.9 Relationship between barramundi serum anti- V. harveyi antibody activity and 
V. harveyi inhibitory activity (relative to pooled non-immune standard sera) showing no 
significant correlation (P > 0.05) when examined by individual treatment group. A. 
Bacterin administered by anal intubation (r = 0.161, n = 10). B. Individuals from saline 
treated control groups displaying bacteriostatic and/or anti- V. harveyi antibody activity (r 
= 0.077, n = 23). 
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Figure 5.10 Non-specific immune parameters in barramundi 10 and 21 days after secondary 
immunisations with V. harveyi bacterin (bact) or saline control (con) via intraperitoneal 
injection (IP), immersion (IMM), anal intubation (Al) or naive to immunisation and 
handling. A. Phagocytic indices of anterior kidney macrophage suspensions, all values are 
means + SE (n = 10) and disparate superscripts show significant differences (P < 0.001, 
Kruskal-Wallis test) B. Serum lysozyme activity, all values are means + SE (n = 10) (no 
significant difference, P = 0.93). 
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5.4 DISCUSSION 
This study has shown that barramundi respond systemically, in terms of antibody, to whole-
killed bacterial cell antigens from V. harveyi when administered by IP injection, immersion 
or anal intubation, although a similar mucosal response was not detected. It also provides 
more evidence possibly supporting the existence of immunological memory, given the four-
fold increase in specific antibody activity after secondary IP administration of the bacterin. 
Furthermore, a correlation between specific antibody activity and bacterial inhibitory 
activity was noted when fish across all treatment groups are examined, although not when 
individual groups were analysed. 
Induction of systemic antibody after peranal bacterin delivery demonstrates the success of 
antigen uptake in the posterior intestine of barramundi, and therefore indicates that the 
potential of orally delivered vaccines is worth investigating. Previous studies have shown 
systemic antibody responses after peranal (Rombout et al., 1986; Joosten et al., 1986; Palm 
et al., 1998; Cain et al., 2000) and peroral (Ainsworth et al., 1995; Palm et al., 1998) antigen 
delivery, although reports of protection from the gut delivery route show that it provides less 
protection in comparison to that provided after immersion or IP injection delivery. Oral 
delivery of V. anguillarum bacterin to ayu, Plecoglossus altivelis, has been protective 
against vibriosis (Kawano et al., 1984; Kawai and Kusuda, 1995) but protection was limited 
by time. 
The apparent anti-V. harveyi antibody activity noted in some individuals in control groups 
may be due to previous exposure of controls to the bacterium, cross-reactivity of existing 
antibodies to V. harveyi antigens or, inaccuracies and lack of specificity of the ELISA. 
Inclusion of pooled non-immune standard sera on every plate and the consistent lack of 
antibody activity in this standard probably rules out the latter explanation. Previous exposure 
to V. harveyi is possible given the global distribution of the bacterium. An equally likely 
explanation is cross-reactivity of existing antibodies with V. harveyi antigens. Immunoblots 
have shown reactivity of serum antibody from non-immunised barramundi with 
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lipopolysaccharide (LPS) from Escherichia coli and with sonicated cells of V. harveyi 
(Bridle, 2000). This suggests that there may be common epitopes within the LPS of Gram 
negative bacteria to which some barramundi displayed specific antibody. If this is the case 
then some bacterin-treated fish may also have had cross-reactive antibodies which would be 
indistiguishable by the ELISA. Regardless of whether the specific antibody in control fish 
was due to previous exposure to V. harveyi or cross-reactive antibodies, the impact of such a 
scenario complicates the interpretation of the results. However, even though for IMM and 
AI treatment groups there were no statistically significant differences in mean antibody 
activity in bacterin and saline treatments, there was a trend for higher activity in the 
bacterin-treated fish where a higher proportion of individuals responded. The fact that the 
majority of individual fish responded in terms of specific antibody to the bacterin whereas 
only a small proportion of saline-immunised fish displayed antibody activity would suggest 
that the antibody response to the bacterin was specific. 
The administration route-dependent increase in serum antibodies observed in this study 
concurs with findings of Jenkins et al. (1994) who reported higher levels of plasma antibody 
after IP delivery of human gamma globulin to tilapia, Oreochromis mossambicus, than after 
either anal or oral delivery. More recently, Palm et al. (1998) reported little difference in 
serum antibody titers of rainbow trout, 0. mykiss, after IP and IMM delivery of V. 
anguillarum bacterin and these titers were substantially higher than those recorded in the 
majority of fish after oral bacterin delivery. Additionally, these investigators found little 
difference in survival after bacterial challenge between all immunised groups. In this case it 
seems that low levels of specific antibody are sufficient for protection and it is possible that 
there is a cut off point where higher antibody levels do not lead to increased protection. 
These are interesting results as they seem to contradict observations on antibody responses 
made in the present study and previously expressed views that the degree of protection 
depended on the bacterin administration route or procedure (Midtlyng et al., 1996a; Thune 
et al., 1997; Nakanishi and Ototake, 1997; Quentel and Vigneulle, 1997). Differences in 
observations may be due to challenge methods, although challenges in these studies were 
water—borne, some were via cohabitation (Midtlyng et al., 1996b) and others by adding 
virulent cells to the water (Thune et al., 1997). 
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A particularly pertinent finding of this study was that all the IP bacterin-treated fish 
displayed a serum antibody response and these sera displayed substantial V. harveyi 
inhibitory activity regardless of the magnitude of specific antibody activity. Firstly, this may 
indicate that the bacterin elicited a potentially protective response, at least in the specific 
humoral arm of the immune system. Secondly, this response may not be a function of the 
magnitude of the antibody response, as suggested by the lack of correlation between the 
antibody activity and the bacterial inhibitory activity. As alluded to above, it may be that 
antibody is responsible for the bacterial inhibitory activity but a saturation effect may occur 
where more antibody activity does not increase inhibitory activity. Given the data and the 
means by which it was collected it is not possible to discern a causal link between antibody 
activity and bacterial inhibitory activity. 
Although other humoral serum factors such as complement, lysozyme and C-reactive 
protein have antibacterial properties (Yano, 1996), these are thought not to be responsible 
for the bacterial inhibitory activity observed in this experiment. Complement has known 
bactericidal activity for a range of teleosts and the classical complement pathway is 
activated by the antibody-antigen complex (Sakai, 1992). However, the bacteriostatic assays 
were conducted with heat-treated, and consequently complement-inactivated, serum samples 
as well as untreated samples with no difference noted. It could be argued that complement 
would be inactivated in the untreated samples as well given components that are heat labile 
over time and even at temperatures of -20°C (Sakai, 1992). It is therefore unlikely that 
complement was involved in V. harveyi inhibitory activity. There is also solid evidence for 
the lack of involvement of lysozyme in the observed inhibitory activity. Firstly, in the 
absence of a complement-derived membrane attack complex to initially disrupt the bacterial 
cell walls, lysozyme would be less effective against Gram negative bacteria (Yano, 1996), 
though in rainbow trout a lysozyme variant, designated type 11, was found to act directly on 
four Gram negative bacterial fish pathogens at physiological serum concentrations (Grinde, 
1989). Secondly, there were no differences detected in serum lysozyme activity between 
treatment groups within this study. Other serum factors such as C-reactive protein (CRP) 
and other acute phase proteins would probably only be in circulation at basal levels given 
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the time between immunisation (primary and secondary) and sampling, unless there was 
some external injury or inflammation. CRP does activate humoral defences via complement 
activation (Ellis, 1999b) and when isolated from rainbow trout has been shown to inhibit in 
vitro growth of V. anguillarum (Nakanishi et al., 1991). 
Although there was no correlation between antibody activity and bacterial inhibitory activity 
it is interesting that IP-immunised fish displayed high levels of inhibitory activity and 
varying levels of antibody activity. It may be that relatively low levels of anti-V. harveyi 
antibodies are sufficient to inhibit V. harveyi in the in vitro assay system used. It has been 
shown previously that protection does not always correlate with antibody activity, indeed, 
protection against bacterial challenge has been reported in immunised fish demonstrating no 
systemic antibody activity (Ellis, 1988a). It may be that small quantities of antibody are 
sufficient or that cell-mediated mechanisms are partially responsible. In this experiment, 
activity noted in the serum alone rules out direct involvement of the cell-mediated arm. 
A clear way to elucidate the role of antibody in bacterial inhibitory activity and protection 
would be by passive immunisation then challenge with live bacteria. Unfortunately it was 
not possible to challenge barramundi with virulent V. harveyi in our laboratory, due to 
quarantine regulations. 
In this experiment the bacterin intubated into the hind gut of the fish consisted of washed 
formalin-killed whole cells, perhaps one reason for the lower response compared to the IP 
treated fish was the lack of sufficient quantity of soluble factors in the bacterin. A previous 
experiment using V. anguillarum found that phagocytosis and uptake of whole cells by 
enterocytes did not occur in the hind gut of rainbow trout and carp whereas antigen uptake 
was observed in vaccine culture supernatant and purified lipopolysaccharide (Joosten et al., 
1996.) On the other hand, Agius et al (1983) found better protection after challenge in 
rainbow trout immunised perorally with whole-killed V. anguillarum cells than with an 
extract of centrifuged culture, whether whole cells, particles or soluble antigenic 
determinants were taken up in the appropriate section of the gut is not clear. Similarly, Palm 
et al. (1998) found that oral delivery of whole-killed V. anguillarum cells conferred 
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protection in a laboratory challenge, again the nature of the antigen taken up was not 
investigated. 
In terms of antibody production antigen dosage to the hind gut appears important in 
determining the magnitude of the response. The present study found only a minimal 
antibody response after an initial and booster anal immunisation with bacterin. Whereas 
Rombout et al. (1989) found repeated doses of ferritin delivered anally or orally, in 
association with food, elicited anti-ferritin antibody levels in carp plasma comparable to 
those reached after intramuscular injection. Jenkins et al. (1994) reported a considerable 
specific antibody response in the plasma of tilapia, 0. mossambicus, after a single oral or 
anal immunisation with human gamma globulin (HGG). However, the antigen was delivered 
with the saponin adjuvant Quil-A (Jenkins et al. ,1994). 
None of the non-specific immune responses quantified showed any difference between any 
of the treatment groups. Serum lysozyme activity indicated that there was no enhancement 
or, that it was resolved by the time of sampling. Similary, head kidney macrophage 
phagocytic ability showed generally no enhancement, however phagocytic activity in the 
naïve group was significantly higher at 10 days post booster immunization than at 21 days in 
groups anally intubated with bacterin or saline and the naïve group. A possible explanation 
is that the phagocytic activity may have been resolved by the time 21 days had elapsed. 
Macrophages, though easily stimulated in vitro, may have passed the activation stage. 
The results presented here show that barramundi respond systemically to V. harveyi bacterin 
when it is delivered via IP injection, exposure to GALT and immersion and that in 
accordance with many authors the response was highest in injected fish relative to intubated 
and immersed fish. 
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CHAPTER 6 
THE ROLE OF LIPOPOLYSACCHARIDE FROM Vibrio harveyi AS AN 
IMMUNOGEN AND PROTECTIVE ANTIGEN COMPARED TO BACTERIN 
6.1 INTRODUCTION 
Lipopolysaccharide (LPS) is a constituent of the outer cell membrane lipid bilayer of Gram 
negative bacteria which has both toxic properties and immunomodulating activities. It 
consists of three important regions, the outer oligosaccharide side chain responsible for 0- 
antigenic specificity of individual species, a core polysaccharide common to virtually all 
Gram negative bacteria and, an inner lipid A structure (Burrell, 1990). A smaller form of 
LPS which lacks the 0-antigen is designated rough (R) type whereas LPS with the 0- 
antigen is designated smooth (S) type (Sprott et al., 1994). Many strains of bacteria produce 
both LPS types, in varying proportions, but some strains only produce the R-type (Sprott et 
al., 1994). LPS is also known as endotoxin which is the naturally occurring LPS 
macromolecule with associated membrane or cytoplasmic proteins (Burrell, 1990). The lipid 
A structure is thought to be primarily responsible for endotoxic activity of the molecule, 
although other structures have biologically stimulating functions (Burrell, 1990). 
Immunomodulatory effects of LPS are well documented and the molecule interacts with 
numerous humoral and cellular factors (Morrison and Ryan, 1979), including alternate 
complement pathway activation by oligosaccharide side chain (Morrison and Kline, 1977), 
influencing levels of C-reactive protein and cortisol in plaice, Pleuronectes platessa L., 
(White et al., 1984) and stimulation of mammalian macrophages to produce and release 
immunoregulatory factors such as prostaglandin (Kunkel et al., 1986) and tumor necrosis 
factor (TNF-a) (Sayers et al., 1987). In mammals, LPS is a powerful B lymphocyte mitogen 
as well as being an activator which are seemingly separable roles (Burrell, 1990). This 
independence was demonstrated by Haeffner-Cavaillon et al. (1982) when they reported that 
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polysaccharide rich fractions were not mitogenic to rabbit splenocytes but did induce Ig 
synthesis in the B cell population. 
Although LPS can be very toxic in some mammals causing severe hypotension and death, 
fish are reportedly less susceptible to these toxic effects (Berczi et al., 1966; Wedemeyer 
and Ross, 1969; Paterson and Fryer, 1974; Harbell et al., 1979). In fact the 
immunomodulating activities of LPS can have a beneficial effect on the immune response 
by up-regulating non-specific immune parameters such as respiratory burst activity of 
mammalian macrophages (Pabst and Johnston, 1980). In fish, Solem et al. (1995) 
demonstrated the ability of LPS from Aeromonas salmonicida to stimulate in vitro 
macrophage respiratory burst and phagocytic activity in Atlantic salmon, S. salar, Similarly, 
enhancement of phagocytic activity of leucocytes in the eel, Anguilla japonica, after 
injection of LPS from Edwardsiella tarda has been reported (Salati et al., 1987). More 
specifically, antibodies and agglutinins have been induced in brown trout, Salmo trutta, after 
immunisation with LPS from Salmonella typhimurium (Ingram and Alexander, 1980). 
Nalchla et al. (1997) found that rainbow trout, Oncorhynchus mykiss, generated anti-LPS 
activity in serum after repeated injections with LPS from A. salmonicida and that this 
activity was prolonged when LPS was incorporated into liposomes. 
On a more holistic level, immunisation of fish with crude preparations of LPS has been 
shown to be protective against some bacterial diseases (Baba et al., 1988; Rogers, 1990). 
Thus LPS is very immunogenic in fish and is the main surface antigen of the pathogenic 
vibrios (Chart and Trust, 1984) Lipopolysaccharide is thought to be the protective antigen of 
the fish pathogenic bacteria V. ordalii (Velji et al., 1990; Velji et al., 1991), V. anguillarum, 
V. salmonicida and Y. ruckeri (Press and Lillehaug, 1995). Similarly, Al-Harbi and Austin 
(1992a) found injected LPS extracted from a Cytophaga-like bacterium to be protective in 
turbot, Scopthalamus maximus, against challenge from the bacterium. 
In the context of a vaccine component, it is recognised in mammals that immunisation with 
a bacterial vaccine or isolated endotoxin results in antibody directed primarily against the 0- 
antigen (the repeating oligosaccharide) component of LPS (Morrison and Ryan, 1979). 
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However, LPS is considered to be a thymus independent (or T-helper cell independent) 
antigen and induces antibody responses without the activation of T cells and with little 
immunological memory induction (Roitt et al., 1996). Lipopolysaccharide from an A. 
salmonicida vaccine has been shown to be present in spleen and head kidney 
melanomacrophages 16 weeks after intraperitoneal injection of vaccine (Press et al., 1996). 
These authors suggest that such retention of antigen in lymphoid organs such as the spleen 
and head kidney may be important in the formation of immunological memory. Though 
retention of antigen itself does not necessarily imply a protective immune response in fish 
(Press et al., 1995) the persistence of the antigen within the fish does play a role, along with 
dose and administration route, in the magnitude of immunological memory (Rijkers et al., 
1980). These processes in fish are not yet fully understood but it seems possible that LPS 
may be retained within lymphoid tissue macrophages and thus play a role in prolonged 
protection and consequently be an antigen worth considering as a vaccine component. 
Along with a fuller understanding of the processes involved in the vaccine-induced disease 
protection there is a need to identify the protective components of vaccines so that they may 
best be administered to the fish. To elucidate what effect V. harveyi LPS may have on 
barramundi this study compares the effect of immunisation with bacterin and LPS in terms 
of some non-specific responses and antibody responses. 
6.2 MATERIALS AND METHODS 
6.2.1 Fish husbandry 
Procurement and husbandry of barramundi were as described in section 3.2, although the 
acclimation period was 4 weeks and there was one aquarium per treatment, each containing 
10 fish. Before immunisations aquaria were randomly allocated a treatment. A selection of 
fish naive to all treatments, including placebos, served to provide a pool of non-immune sera 
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in lieu of pre-bleeds. The fish were weighed at the commencement of the trial and the mean 
weight of each treatment group appears in Table 6.1 
Table 6.1 Mean weight (± SE; n = 12) of barramundi in each treatment group at the 
commencement of the immunisation experiment using V. harveyi bacterin, 
lipopolysaccharide (LPS) or saline delivered by intraperitoneal injection (IP) 
Treatment group Mean weight (g) 
B acterin 40.3 ±2.2 
LPS 52.7 ± 3.5 
Saline 42.9 ± 7.7 
6.2.2 Bacterin Preparation and administration 
The bacterin was prepared as described in section 3.3 and, as was the case in chapter 5, V. 
harveyi strain no. 9050405 was used as the culture bacterium. Anaesthetised fish were 
injected intraperitoneally with 0.13 mL inocula for a dose of 0.08 mg (wet weight bacterial 
cells) per gram of fish. 
6.2.3 Lipopolysaccharide extraction and administration 
For isolation of LPS V. harveyi was grown in NB2 as 1 L volumes in 3 L flasks in a shaking 
water incubator at 30°C for 6.5 h. Lipopolysaccharide was then extracted from bacterial 
cells by a procedure modified by Sprott et al. (1994) from that of Galanos et al. (1969). This 
procedure required the harvesting of V. harveyi in exponential growth phase, so that the 
majority of cells would be robust and not damaged. To ensure cultures were in exponential 
growth phase after an incubation period of 6.5 h, cell densities were monitored every 0.5 h 
by measuring optical density at 550 nm on a spectrophotometer (UV-1200 series, 
Shimadzu). Briefly, the extraction procedure was as follows: 6 x 1 L cultures were chilled to 
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4°C and cells harvested by centrifugation at 100 x g for 10 min. Pellets were resuspended 
with a homogeniser in 50 mL of cold deionised water, then again centrifuged for 10 min at 
12000 x g. Cells were then suspended in 1 mL of cold deionised water before being 
homogenised in 50 mL of cold methanol and centrifuged again for 10 min at 8000 x g. The 
pellet was then suspended in 50 mL of cold acetone, homogenised and centrifuged as above. 
The acetone washing step was repeated and the pellet was lyophilised overnight. LPS was 
extracted by combining 25 mL of a phenol (13.3% v v -1 ), chloroform (33.3% v v -`) and 
petroleum ether (53.3% v v - ') mixture (PCP) with dried cells and homogenising for 30 s. 
Suspension was then centrifuged for 5 min at 9200 x g. Supernatant was collected and the 
pellet was resuspended in PCP and centrifuged as before. Supernatants were then combined 
and filtered through Whatman no. 1 paper then concentrated by evaporation under nitrogen 
gas at 50°C and centrifuged for 10 min at 12000 x g. The phenol liquid was aspirated with a 
syringe and needle and 10 mL of methanol added and suspension was centrifuged for 15 min 
at 12000 x g, methanol washing was repeated twice before the pellet was lyophilised 
overnight. The pellet was then suspended in 20 mL of 0.1 mM MgC1 2, homogenised and 
ultracentrifuged at 200000 x g for 4 h. 
The total yield of LPS was approximately 1.5 mg. This was diluted in 3 mL of sterile saline 
(0.15 M NaC1) to give a final LPS concentration of 500 pg mL -1 . Aliquots from this stock 
were electrophoresed on SDS-PAGE and silver stained to check for purity and analysed for 
protein content with a Bradford microbioassay kit (Bio-Rad). The result was a protein 
concentration of 17 lig mL-1 or approximately 3%. Anaesthetised fish were immunised with 
40 lig of LPS in sterile saline as 0.1 mL inocula. Control fish were injected with 0.13 mL of 
sterile saline. 
Twenty one days later all fish were anaesthetised then re-immunised as above for bacterin 
but with 30 vg per fish of LPS, the mean fish weight was 71.2 ± 15.9 g. 
For comparative purposes a crude preparation of LPS was extracted from V. harveyi by 
proteinase K digestion according to Hitchcock and Brown (1983). The bacterium was 
cultured to exponential growth as described above, then 1.5 mL of the suspension was 
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centrifuged in a microcentrifuge for 3 min. The pellet was resuspended in SDS-PAGE 
reducing sample buffer (section 2.2.2) and heated at 100°C for 10 min, after which 25 lig of 
proteinase K (Boehringer Mannheim) was added to the suspension which was then 
incubated at 60°C for 1 h. The preparation was then stored at —20°C until used. 
6.2.4 Sampling procedures 
Seven days after booster, half the fish (i.e. five individuals) from each group were lethally 
anaesthetised with benzocaine (200 mg LI) then serum and mucus (both skin and gut) 
samples taken prior to removal of head kidney and subsequent harvest of macrophages. 
Serum samples were allowed to clot overnight at 4°C then stored at —20°C. Mucus samples 
were collected and stored as previously described in section 3.4 as were head kidney tissues. 
Remaining fish were sampled as above at 21 days post booster. 
6.2.5 Immune assays 
Macrophages were harvested as described in section 3.5.1 then incubated with yeast cells to 
measure phagocytic activity (section 3.5.2). Assays were also performed to assess serum 
lysozyme activity, anti-V. harveyi antibody activity by ELISA and bacteriostatic ability 
(sections 3.5.3-3.5.5). 
The ELISA was identical to that used for the experiment described in Chapter 5, and the 
same calculation was used to determine anti-V. harveyi antibody activity. Although ideally 
LPS should be the coating antigen to detect specific antibody in the LPS-immunised group 
of fish the poor yield meant there was insufficient LPS for use in ELISA calibration and 
subsequent processing of samples. It was therefore decided to use the same coating antigen 
in ELISA for all treatment groups. 
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6.2.6 SDS-PAGE and immunoblotting 
Electrophoretic profiles of various LPS preparations and a commercial preparation of LPS 
purified from Escherichia coli (serotype 026-B6,Sigma) were performed by Ms Melanie 
Rutherford at the Department of Primary Industry, Water and the Environment, Launceston 
using SDS-PAGE with 12% polyacrylamide resolving gels. SDS-PAGE prior to 
electrotransfer to nitrocellulose for immunoblotting was performed under reducing 
conditions on 10% resolving gels using the protocol described in section 2.2.2. Western 
blots to analyse LPS preparations and the bacterin were carried out as described in section 
2.2.5. 
6.2.7 Statistical analyses 
Data were analysed with a one-way analysis of variance (ANOVA) using the JMP 3.2.1 
statistical package. ANOVA assumptions of data normality and homogeneity of variances 
were tested using the Shapiro-Wilk W test and Bartlett's test respectively. Nested analyses 
were used to ascertain differences due to time within treatments (i.e. sampling times of 7 and 
21 days post booster). As found in previous experiments serum V. harveyi inhibitory activity 
data fulfilled neither assumptions of normality nor homogeneity of variances and was 
therefore analysed using the Kruskal-Wallis non-parametrical statistical test. In examining 
associations between specific antibody activity and V. harveyi inhibitory activity correlation 
coefficients were determined and tested for significance (Sokal and Rohlf, 1987). Significant 
differences were highlighted as multiple comparisons of means (Tukey-Kramer HSD test) 
were carried out. When examining differences in all parameters between aquaria and 
treatment groups at 7 and 21 days post booster, data were pooled if analyses had P values > 
0.1. For all tests a significance level of P < 0.05 was adopted. 
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6.3 RESULTS 
6.3.1 Lipopolysaccharide extraction 
LPS extraction from V. harveyi was successful in terms of purity (Figure 6.1), however a 
yield of 1.5 mg was lower than expected. Yield is dependent on the state of the cells at time 
of harvest and is also influenced by the extraction technique. The technique used in this 
study was suitable for rough type (R-type) LPS. As the R-type LPS lack the 0-antigen, the 
mobility patterns seen on PAGEs differ to those of the S-type LPS which has a marked 
multi-banding or laddering pattern. The LPS from V. harveyi was thought to be R-type due 
to the lack of laddering as seen on PAGEs of a crude LPS product extracted via proteinase K 
digestion of V. harveyi lysates. 
6.3.2 Immune assays 
There seemed to be a lack of macrophage activation by LPS, given that phagocytic indices 
of head kidney macrophage cell suspensions showed no significant difference (P = 0.47) 7 
days after the booster (Figure 6.2). Unfortunately there are no results for this parameter at 21 
days post booster due to bacterial contamination of the cell suspension. LPS did, however 
have an effect on lysozyme activity with all groups demonstrating significantly different 
levels in activity (P < 0.001) (Figure 6.3). Lysozyme activity was highest in the control 
group with both LPS- and bacterin-immunised groups showing depressed activity. There 
was however no difference within treatment groups at 7 or 21 days post booster for this 
parameter (P = 0.36), thus data were pooled at this level. 
A specific humoral response was detected in both LPS and bacterin treatment groups with 
specific antibody activity detected being highly variable. When antibody responses of 
individual fish were examined (Figure 6.4A), five of the ten responded to LPS and five of 
nine to the bacterin (there was one mortality in the bacterin-immunised group), no antibody 
activity was detected in the control group. Statistical analysis showed no significant 
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differences within groups at 7 and 21 days post booster (Figure 6.4B), therefore the data 
were pooled. There was no significant difference in antibody activity between LPS- and 
bacterin-immunised groups. The bacteriostatic activity of the serum was also evident 
(Figure 6.5) and was significantly higher in the bacterin-immunised fish (P= 0.036). There 
was also some bacteriostatic activity in the control fish but this was due to 2 individual fish 
(Figure 6.5A). LPS-treated fish had lower levels of bacteriostatic activity but most did show 
some activity. Contrary to observations from a previous experiment there was no correlation 
between specific antibody activity and bacteriostatic activity of the serum (Figure 6.6). This 
lack of correlation between these parameters was noted when looking at the treatment 
groups both separately and combined. 
Western blot analysis of LPS preparations and the bacterin (Figure 6.7) clearly show that 
both LPS- and bacterin-immunised fish have antibodies directed against E coli LPS, 
although there appears to be no reactivity against the proteinase K digestion product (crude 
V. harveyi LPS) or the bacterin. 
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Figure 6.1 SDS-PAGE showing comparative purity of LPS extracted from  V. harveyi 
(lane 1) by method of Sprott et al. (1994), LPS derived from proteinase K digestion of 
V. harveyi lysates (Hitchcock and Brown, 1983) (lane 2) and LPS from E. coil 
(Sigma) (lane 3) with the area of 0-antigen indicated. The gel was silver stained. 
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Figure 6.2 Phagocytic indices for bammundi anterior kidney macrophage suspensions 7 
days after booster immunisation with LPS, V. harveyi bacterin or saline as a control, values 
are means + SE (no significant difference, P = 0.47). 
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Figure 6.3 Serum lysozyme activity for barramundi after booster immunisations with LPS, 
V. harveyi bacterin or saline as a control. Data were pooled as there was no difference 
between 7 and 21 days post booster. Values are means + SE, disparate superscripts show 
significant differences between treatment groups (P < 0.001, Tukey-Kramer HSD test). 
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Figure 6.4 Specific anti- V. harveyi antibody activity of barramundi serum after booster 
immunisation with V. harveyi bacterin, LPS or saline. A. Individual fish within a treatment 
group. B. Activity of fish per treatment group, there was no activity detected in saline 
treated fish. Data were pooled as there was no difference between 7 and 21 days post 
booster. Values are means + SE (no significant difference). 
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Figure 6.5 V. harveyi inhibitory activity of barramundi serum relative to pooled non-
immune standard sera after booster immunisation with V. harveyi bacterin, LPS or saline. A. 
Individual fish within a treatment group. B. Fish per treatment group, data were pooled as 
there was no difference between 7 and 21 days post booster. Values are means + SE and 
disparate superscripts show significant differences between treatment groups (P = 0.03, 
Kruskal-Wallis test). 
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Figure 6.6 Relationship between anti-V. harveyi antibody activity and V. harveyi 
inhibitory activity (relative to pooled non-immune standard sera) of barramundi serum 
showing no significant correlation (P> 0.05). A. Bacterin immunised fish (r = 0.285, n = 
9). B. LPS immunised fish (r = 0.311, n = 10). C. All treatment groups combined (r = 
0.195, n = 29). 
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Figure 6.7 Western blot analysis V. harveyi LPS (proteinase K digest) (lane 1), V. 
harveyi sonicate (lane 2) and E. coli LPS (Sigma) (lane 3). A. Probed with pooled 
bacterin-immunised sera at 1:6 B. Probed with LPS-immunised pooled sera at 1:6 
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6.4 DISCUSSION 
The results presented here demonstrate the ability of barramundi to respond 
immunologically to both a V. harveyi bacterin and LPS extracted from this bacterium. The 
extent of this response was varied and more pronounced in the specific humoral arm of the 
immune system than the non-specific parameters measured. LPS is very immunogenic in 
fish and is recognised as the predominant structure to which antibodies are directed when 
Atlantic salmon, S. salar, are immunised with cells of V. salmonicida and V. anguillarum 
(Bogwald et al., 1991). Whether this is true in this instance is not known as immunoblot 
analyses of both the bacterin and LPS were inconclusive, although both LPS- and bacterin-
immunised fish had antibodies reactive with LPS from E. coll. 
Variation in the antibody response to LPS may have been due to a number of reasons. First, 
the use of killed-V harveyi cell sonicate as the coating antigen may have decreased the 
sensitivity of the ELISA. Second, individual variation between fish in the response may be 
expected as some fish may be non-responders. Third, there may be a dose effect i.e. it may 
have been too high or too low. Previously reported doses of LPS for fish vary widely, 
ranging from 20 ng kg' for coho salmon, Oncorhynchus kisutch, (Velji et al., 1991), 10 mg 
kg- ' for turbot, Scophthalmus maximus, (Al-Harbi and Austin, 1992) and 50 mg kg - ' for 
Atlantic salmon, S. salar, (Dalmo and Bogwald 1996), there is no published information on 
LPS administration to barramundi. Fourth, LPS may be more immunogenic in its natural 
state with its associated membrane and cytoplasmic proteins. Although many studies have 
used isolated LPS as an antigen (Velji et al., 1991; DaImo and Bogwald 1996; Nakhla et al., 
1997), some studies have involved immunisation of fish with whole killed bacterial cells 
then used inununoblots and ELISAs to elucidate the roles of particular antigens like LPS 
(Hoel et al., 1997). This latter method may be more pragmatic, at least when investigating 
antibody responses, as the purified LPS does not exist naturally and therefore assessments of 
its biological activity need to done with caution (Burrell, 1990). However, it would be 
difficult to appraise responses to particular antigens of other immune parameters without 
immunising with a purified antigen. With this in mind, the study was designed to compare 
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the response of extracted LPS with the whole cell bacterin in an attempt to see if LPS 
enhanced non-specific immunity in conjunction with eliciting an antibody response. The 
antibody response to the bacterin was also variable, with only five of the nine fish 
responding which was similar to the responding rate of LPS-immunised fish which was five 
from ten. Variable antibody response after immunisation is not an unknown observation in 
fish, non-responsiveness of B cells in the gut of rainbow trout, 0. mykiss to key-limpet 
hemocyanin (KLH) has been reported though there was no concomitant systemic non-
reponsiveness (Jones et al., 1999). In carp, C. carpi°, individual fish with a high and low 
antibody response are common enough for work to be performed on selection and 
propagation for further research (Wiegertjes et al., 1995). 
The V. harveyi inhibitory activity of the sera was highest for the bacterin-immunised fish 
which concurs with results noted in previous experiments reported in Chapters 4 and 5. 
Although two control fish also showed high bacteriostatic activity (Figure 6.5B), the activity 
noted in the LPS-immunised fish was more consistent. In this study no correlating 
relationship was found between anti-V. harveyi antibody activity in the serum and the 
bacterial inhibitory ability of the serum. This is contrary to what was reported Chapter 5. 
However, the serum antibody activities of IP bacterin-injected fish seen in that experiment 
were higher than reported here. This discrepancy in antibody activity maybe due to 
individual variation, assay variability or variation in the vaccine. Different batches of 
vaccine were used for each experiment and though they came from the same stock culture 
and were cultured under the same conditions, there may have been subtle differences caused 
by mutations within the original culture for example which may have altered 
immunogenicity. The consistently high serum bacteriostatic ability of bacterin-immunised 
fish suggests that this activity was a result of the immunisation. However, information on 
the bacteria-inhibiting mechanism of the immune serum has not been gained. The 
bacteriostatic assay has been performed with samples that were heat treated to inactivate 
complement (45°C for 10 min) and with untreated samples, with little difference being 
noted. It could be argued that in both untreated and heat treated samples complement may 
have already been inactivated in storage given its lability. If this was the case, then antibody 
may have been responsible for the bacteriostatic ability of the immune serum. Fish antibody 
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acts as an opsonin and can bind and agglutinate bacterial cells or neutralise antigens by 
blocking a critical function (Kaattari and Piganelli, 1996). The assay is based on the uptake 
of MTT by living bacterial cells and its subsequent reduction by mitochondria' enzymes to 
formazan, a process that may have been inhibited by opsonisation or agglutination. The 
other possibility, as discussed in Chapter 5, is that an unmeasured serum factor was 
responsible for the activity. In any case the apparent bacteriostatic activity of the immune 
serum suggests that vaccination with V. harveyi bacterin by IP injection may induce 
protection. In the absence of data from vaccination and challenge trials using the relevant V. 
harveyi isolate making such a link is tenuous. 
LPS was demonstrated as an antigen in barramundi by ELISA, though its protective role 
remains unclear. The lower lysozyme activity noted in LPS-immunised fish relative to 
bacterin-immunised and control fish may or may not be a treatment effect. There are a 
number of reports where lysozyme activity of the serum has been shown to increase after 
immunisation with various preparations (Rainger and Rowley, 1993; Chen et al., 1998). 
However, Ainsworth et al. (1995) found no detectable trends. Increase in lysozyme activity 
in plasma seems a typical response of rainbow trout under acute stress (Fevolden and Roed, 
1993; Demers and Bayne, 1997), it has even been mooted as a possible replacement for 
cortisol as a stress indicator in fish (Fevolden and Roed, 1993). Whether fish in the bacterin 
and control groups were more stressed than LPS-immunised fish is not known though the 
holding facilities and handling procedures were uniform. A group naïve to all treatments, 
including handling, would have been an advantage in this experiment to ascertain base 
levels of lysozyme activity in serum. Such a group was included in the previous experiment 
(Chapter 5), and there was little difference noted between naïve, control and immunised fish. 
The LPS extraction method resulted in a yield lower than expected, given the culture 
volumes used. This may stem from the method used and/or the physiological state of the 
bacterial cultures. The extraction method suitable for R-type LPS was chosen based on the 
banding patterns of a crude LPS preparation from V. harveyi.. The lack of laddering on 
PAGEs suggested that the LPS was R-type. The laddering appearance on gels results from 
the region of LPS comprising the outer oligosaccharide side chain or 0-antigen. This side 
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structure is in fact a heterogeneous mixture of oligosaccharides of various chain lengths and 
subsequently different mobilites on gels. R-type LPS lack this outer side chain. There seems 
to be little or no information on LPS of V. harveyi in the literature and the structure varies 
widely between different strains and species of Gram negative bacteria (Sprott et al., 1994). 
What may cloud the issue even more is that multiple forms of LPS may be produced by a 
single strain of a bacterium depending on culture conditions such as temperature, cell 
densities and nutrition. As pointed out by Sprott et al. (1994), the heterogeneity of LPS was 
not fully appreciated when extraction methods were developed, therefore yields from any 
particular method may be equally varied. Whether or not the heterogeneity of LPS impacts 
on its immunogenicity is not known. 
Regarding the specific antibody responses, the evidence from immunblots using E. coli LPS, 
the crude V. harveyi LPS from the proteinase kinase digest and, the bacterial sonicate 
suggests that antibodies elicited in both bacterin-and LPS-immunised groups may be 
directed against LPS and that there are possibly shared epitopes between both E. coli and V. 
harveyi LPS or, that individuals had a some exposure to environmental Gram negative 
bacteria and LPS. The cross-reactivity with the E. coli LPS is thought likely because in a 
subsequent experiment in our laboratory barramundi immunised with a PBS placebo were 
found to have antibodies reactive with the V. harveyi sonicate in ELISAs, and further that 
these sera were reactive with E. coli LPS as determined by Western blot (Bridle, 2000). The 
lack of any obvious reactivity with V. harveyi sonicate or the proteinase K digest of immune 
sera in Western blots may imply that there is relatively insufficient LPS in these 
preparations to be detected by this method as opposed to the highly-purified commercially 
prepared E. coli LPS. However, reactivity of immune sera with the bacterial sonicate 
detected by ELISA possibly highlights the greater sensitivity of ELISA compared to western 
blot. The disparity between V. harveyi inhibitory activity of non-immunised and immunised 
sera indicates that even though both sera have apparent antibody activity, as measured by 
ELISA, the antibodies in the non-immune sera may be less relevant. Explanations as to why 
placebo-immunised fish displayed V. harveyi inhibitory activity and no specific antibody 
activity are difficult to find. Certainly, it may be due to individual variation given the lack of 
extensive replication in this experiment. 
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CHAPTER 7 
GENERAL DISCUSSION 
Overall, the experiments described in this thesis clearly indicate V. harveyi bacterin to be a 
good vaccine candidate for barramundi. The results consistently demonstrate the ability of 
the bacterin to elicit a systemic immune response in barramundi. Moreover, sera with high 
specific antibody activity also displayed high antibacterial activity, although an association 
between the two was not proven. Clearly the next step is to evaluate the bacterin using 
vaccination/challenge experiments. As alluded to in Chapter 1 studies described in this 
thesis formed only one part of a collaborative effort to develop and evaluate a vaccine and 
unfortunately data from commercial vaccination/challenge trials are not yet available. 
Although it cannot be inferred from the present study that induction of an immune response 
is an indication of effective vaccination, there have been studies that related specific 
antibody to protection from disease. Joosten et al. (1995) and Joosten et al. (1996) found a 
positive correlation between specific antibody and protection using V. anguillarum bacterin 
in carp. Similarly, a positive association has been observed in the humoral response and 
protection after IP immunisation against furunculosis in Atlantic salmon (Midtlyng et al., 
1996a; Midtlyng et al., 1996b; Bricknell et al., 1999), and after IP immunisation against an 
atypical A. salmonicida strain (Gudmundsdottir et al., 1997). However, correlations between 
specific antibody and protection do not always occur (Smith, 1988) and this lack of 
correlation underlines the requirement to identify antigenic determinants within a 
prospective vaccine. A bacterin is a complex mixture of whole cells, extracellular and 
intracellular products some of which will be virulence factors and all may vary in 
immunogenicity. For example, a furunculosis vaccine prepared from extracellular products 
of A. salmonicida elicited systemic antibody in rainbow trout to only four of the fourteen 
proteins present (Hastings and Ellis, 1988). This also highlights the need to investigate the 
specific immunity to particular antigens as potentially protective antigens may or may not be 
immunogenic in the target fish, i.e. some epitopes may be immunodominant (Vallejo et al., 
1992). 
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To be protective antibodies need to exert secondary effector functions other than the primary 
function of binding antigen (Roitt et al., 1996). These functions need to be neutralising in 
some way: they need to block some critical function such as adhesion by a pathogen, 
agglutinate or opsonise it to promote phagocytosis, neutralise any extracellular toxins 
produced as a result of infection or, activate complement to facilitate elimination of the 
microbe (Kaattari and Piganelli, 1996). In the case of V. anguillarum vaccines protection has 
been unequivocally linked to specific antibody by passive immunisation experiments where 
immune sera were derived from injection immunisation (Harrell et al., 1975) and immersion 
immunisation (Viele et al., 1980). However, protection against vibriosis has also been noted 
after hyperosmotic infiltration (HI) and IP immunisations with little or no detectable 
antibody (Croy and Amend, 1977), although in many instances attempts to detect antibody 
used agglutination assays. Lack of detectable antibody indicates that factors other than 
systemic antibody may also be involved in protection, or that agglutinating antibody 
detection methods may be insensitive. Conversely, protection against vibriosis in the 
presence of specific antibody was seen after bacterin delivery via HI and IP injection 
(Antipa and Amend, 1977) and spray immunisation (Gould et al., 1978). So, in the case of 
vaccine-induced protection against disease from V. anguillarum small amounts of systemic 
antibody may be sufficient. Unfortunately, in the example cited above of successful passive 
immunisation using immune sera derived from immersion (Viele et al., 1980) antibody 
levels in the immune sera were not measured. However, in another successful passive 
immunisation experiment where plasma immunoglobulins, derived after immunisation with 
V. ordalii LPS, were injected into coho salmon, no bacterial cell agglutinating antibody was 
found (Velji et al., 1991). Boesen et al. (1999a) found that rainbow trout serum was still 
bactericidal against V. anguillarum when diluted to the extent that it no longer agglutinated 
the bacterium provided a complement source was added. This supports the notion that small 
amounts of antibody undetectable by agglutination assays are sufficient for protection. 
An additional explanation for protection in the apparent absence of antibody relates to the 
routes of immunisation. For example V. anguillarum vaccines are routinely delivered via IP 
injection and immersion (Lillehaug, 1989b) and, as noted previously, are generally 
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successful regardless of the level of systemic antibody. Aside from the cellular mechanisms 
that may be involved, this may indicate that protection occurs at the mucosal or systemic 
level depending on the route of immunisation. Thus to clarify the situation it seems 
imperative to be able to detect mucosal antibody. 
In the experiments described in this thesis systemic antibody after bacterin delivery by 
immersion was detected although at lower levels than those seen after EP administration. 
Production of systemic antibody after immersion immunisation is not surprising given 
antigen uptake occurs across skin (Ototake et al., 1996; Moore et al., 1998) and the gill 
tissue (Smith, 1982; Zapata et al., 1987) and appears in the anterior kidney and spleen after a 
few hours (Smith, 1988). However, antibody was undetectable in barramundi mucus and, as 
discussed in Chapter 4, is possibly because the detection methods were not sensitive enough. 
Detection of antibody in mucus samples by ELISA has been reported after enteric delivery 
of a reference antigen, human gamma globulin (HGG), to tilapia (Jenkins et al., 1994) and, 
after IP and oral delivery of Edwardsiella ictaluri antigen to channel catfish (Ainsworth et 
al., 1995), although at very much lower levels than those seen in serum. It seems unlikely 
that there was no antibody present in barramundi mucus given published data on existence 
and elicitation of mucosal Ig in numerous species (Table 1.1). 
Elevated humoral responses observed after secondary (booster) IP immunisations in all 
experiments suggested a piscine equivalent of an anamnestic response. The experiment 
described in Chapter 4 showed a three-fold increase in antibody activity after booster 
immunisations. In this experiment the use of oil-based adjuvant in both primary and 
secondary immunisations may have been responsible for the secondary rise in antibody 
activity. Previous reports of a second peak in antibody titer (Lamers, 1986) and antibody-
secreting cells in the head kidney (Davidson et al., 1993) over time after only a primary 
immunisation have been attributed to an adjuvant effect. However, heightened antibody 
responses after IP booster were found in a subsequent experiment (Chapters 5) where no 
adjuvant was used. One of the limitations of the design of each of the experiments was that 
no groups of fish were given a primary immunisation only. Such a group may have clarified 
observations that elevated humoral responses were actual secondary responses and not a 
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result of the kinetics of the response. Thus results need to be interpreted in that context. 
However, if the peak antibody titer after primary immunisation occurred within the period 
before the secondary immunisation then subsequent increases could be attributed to the 
secondary immunisation. In the present experiments, the time between primary and 
secondary immunisations was 21 days and it is possible that a primary peak occurred within 
that time. Previous studies indicate that peaks in antibody levels in fish occur within a range 
of time frames but these are probably dependent on the nature of the antigen, the dose, 
administration route and the water temperature. The serum antibody response of channel 
catfish to a primary IF immunisation with E. ictaluri bacterin showed a peak after 21 and 28 
days for two different experiments with the disparity attributed to temperature differences 
(Vinitnantharat and Plumb, 1992). Temperature has been shown to influence the magnitude 
and kinetics of an antibody response in hybrid sunshine bass (Morone chrysops X Morone 
saxatilis) with lower than optimal temperatures for the hybrid slowing the rate and 
decreasing the magnitude of the response to A. salmonicida (Hrubec et al., 1996). Serum 
antibody peaks in rainbow trout administered Y. ruckeri bacterin via IP injection were found 
after 28 days (Verlhac et al., 1996), however in this example the peak may have been earlier 
or even later as fish were only sampled every 14 days. Similarly in rainbow trout, after IP 
injection with bivalent vaccine made up of V. anguillarum and A. salmonicida antigens, 
Lunden et al. (1998) found antibody against V. anguillarum increasing 12 weeks post 
vaccination but a peak after 28 days for antibody against A. salmonicida. Secombes et al. 
(1982) found peak antibody in carp serum 35-42 days after IP injection with HGG then a 
decline. Given these time frames for antibody responses it is feasible that in my study the 
antibody levels were at least near peak levels within 21 days of the primary immunisation. 
However, without sufficient data on the systemic antibody response of barramundi to 
bacterin it is difficult to hypothesise on the kinetics of the response. 
An elevated antibody response was not seen in groups immersed nor anally intubated with 
bacterin. The kinetics of the humoral response may also be a factor in these cases, fish were 
sampled 10 and 21 days after booster immunisations (immersion and anal intubation) and it 
is possible that the antibody response had not reached its peak in that time frame or had 
reached a peak then declined. Jenkins et al. (1994) found a peak serum antibody response 
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14-21 days after anal and oral delivery of HGG then a decline. The kinetics of the systemic 
response will vary with the administration method as shown by Palm et al. (1998). In 
experiments using a V. anguillarum bacterin administered to rainbow trout these authors 
reported serum antibody peaks 17 days after initial immersion delivery, 24-31 days after IP 
injection and virtually no antibody titers within 42 days after oral delivery. In the same 
experiment peaks after secondary immunisations were after 10 days for orally-treated fish 
and 17 days for both immersion and IP injected groups (Palm et al., 1998). 
Immunological memory in fish is yet to be fully elucidated. If, as Kaattari (1994) proposes, 
the definition for a piscine memory response is based on a distinction in form and function 
leading to enhanced immune reactivity, then a faster antibody response of a higher 
magnitude after secondary exposure partially fits the definition. In the present experiment, 
where bacterin was delivered via IP injection without adjuvant (Chapter 5), there was a four-
fold increase in antibody activity after secondary administration. This observation at least 
fits one of the criteria for immunological memory in fish. Thus, from the data presented here 
it can be concluded that there are indications of an anamnestic response in barramundi, 
further studies investigating the kinetics of antibody responses in barramundi to a bacterin 
are required for confirmation. 
In comparison to antibody activities found in subsequent experiments after IP immunisation, 
those found in Chapter 4 are very high with activity units in the order of 200-300 compared 
to less than 20. Reasons for this disparity may be due to the adjuvant effect and/or because a 
bacterin derived from a different strain was used exclusively in this first experiment and 
therefore reagents used in the ELISA varied. It should be pointed out that a degree of 
repetition in some of the experiments described in the thesis was unavoidable. During the 
course of the study two different strains of V. harveyi were used because a more virulent 
strain was identified after initiation of the project. These strains were not previously 
characterised serologically and unfortunately attempts to do so via Western blot were not 
successful. It seems reasonable to assume that increased virulence of one strain may be due 
to some factor not present in the less virulent strain. Olivier et al. (1985) found variable 
immunogenicity from virulent and avirulent strains of A. salmonicida in coho salmon, 
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Oncorhynchus kisutch. It was therefore necessary to use the most virulent strain of V. 
harveyi for subsequent experiments. 
Observations of a systemic humoral response after bacterin delivery via the mucosa suggest 
that both immersion and oral delivery methods have potential. As with bacterin vaccines 
against other vibrio pathogens such as V. anguillarum, V. ordalii and V. salmonicida where 
immersion delivery is effective (Newman, 1993), indications are that the same may well be 
true for vaccines against V. harveyi. A pertinent point is the lack of domestication of 
barramundi and the need to limit the stress involved in vaccination. A systemic response 
elicited after bacterin delivery to the GALT of barramundi via anal intubation suggests that 
oral delivery methods are worth investigation. This has been vigorous area of research as 
vaccine administration perorally is seen as the only stress-free method and is the most 
desirable by aquaculturists (Ellis, 1988b). Problems associated with antigen degradation in 
the gut can be ameliorated by antigen encapsulation, and current research in this area has 
shown promising results (e.g. Joosten et al., 1995; O'Donnell et al., 1996; Azad et al., 
1999). 
Detection of anti-V. harveyi antibody activity in some non-immunised fish from two of the 
experiments complicated interpretation of the ELISA results. As argued in Chapter 5 this 
was thought to be due to cross-reactivities of non-immune sera with some bacterial antigens, 
or previous exposure to V. harveyi and not to inadequacies of the assay. A similar 
observation made in cod, Gadus morhua, was attributed to natural antibodies in the fish 
cross-reacting with bacterial antigens which were not linked to LPS (Espelid et al., 1991). 
Immunoblots using cross-reactive sera from non-immunised barramundi in a related 
experiment carried out in our laboratory (Bridle, 2000) did indicate a role for LPS. These 
immunoblots showed cross-reactivity with LPS from both Escherichia coli and V. harveyi. 
An equally plausible explanation for antibody activity in non-immunised fish is the previous 
exposure theory. The barramundi used in these experiments were hatchery-reared in 
seawater and it is possible that they were exposed to bacteria from the genus Vibrio. Given 
that V. harveyi is a common water-borne organism (Austin and Austin, 1993), this may 
have been the case with some of the barTamundi used in these experiments. In any case, it is 
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believed that the results of the ELISA accurately reflect the humoral responses of 
barramundi to the bacterin. Immune and non-immune control sera were included on every 
plate with consistent results, and there was a trend for higher activity in those experimental 
fish that were bacterin-immunised. Moreover, there was a far more consistent response in 
the bacterin-immunised fish as shown in individual response data (Figures 4.7A and 5.4A). 
The fact that sera with high anti-V. harveyi antibody activity consistently displayed high 
inhibitory activity against the bacterium suggests that such sera may confer protection 
against vibriosis caused by V. harveyi. Results of bacteriostatic assays presented here appear 
contrary to the possibility of low antibody levels being protective. High V. harveyi inhibitory 
activity was only seen in sera of high antibody titer while sera of low or no antibody titer as 
well as all mucus samples showed little or no inhibitory activity. As reported previously, 
protection after immunisation has been demonstrated with little or no serum antibody 
present (Croy and Amend, 1977; Baba et al., 1988; Thorbum and Jansson, 1988). A major 
factor of the present observations is the sensitivity of the bacterial inhibitory assay and it is 
possible that numbers of bacterial cells used in the assay do not reflect cell numbers 
encountered by the primed immune system in the early stages of infection in fish. Although, 
the only definite way to demonstrate vaccine effectiveness is a significant reduction in 
mortality on challenge with the pathogen, a sensitive bacterial inhibitory assay may have 
practical applications. For example use of this relatively simple and inexpensive assay may 
be helpful in monitoring in vivo immunogenicity in various vaccine batches. There is also 
the potential to adapt the assay for use with other bacterial pathogens. 
Lipopolysaccharide extracted from V. harveyi was shown to be immunogenic in barramundi. 
Antibody levels elicited after LPS immunisation were as high as those found in bacterin-
immunised barramundi. However, the antibacterial activity of the sera from the LPS-
immunised group was much lower. As mentioned previously, this observation may relate to 
the sensitivities of the bacteriostatic assay and that numbers of bacteria used in the assay 
may overwhelm antibody levels that may be effective in vivo. Performance of the 
antibacterial assay with a range of concentrations of bacterial cells may have found a point 
where LPS-immunised sera did display some antibacterial activity. Unfortunately it was not 
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possible to repeat the assay due to the small quantities of sera obtained from experimental 
fish and volumes required. An alternative suggestion is that the role of LPS as a protective 
immunogen may be due to mechanisms other than LPS-specific antibody. Immune 
responses to endotoxin, which is the biological form of LPS and includes associated 
membrane proteins, can result in specific antibody production but, can also occur via the 
cell-mediated arm where stimulated cells would facilitate elimination of microbes 
containing endotoxin (Morrison and Ryan, 1979). The role of LPS as a protective antigen 
has been demonstrated in vaccines against some bacterial fish pathogens, including V. 
anguillarum, V. salmonicida and Y ruckeri (Press and Lillehaug, 1995) although the 
mechanisms of protection are unclear. However, the protective role of anti-LPS antibodies 
was shown in a passive immunisation experiment using sera from coho salmon immunised 
with LPS extracted form V. ordalii (Velji et al., 1991). In this experiment naïve fish were 
protected after immunisation with partially purified plasma immunoglobulins derived from 
IP- and immersion-immunised fish however, when these plasma immunoglobulins were 
absorbed against V. ordalii cells prior to injection into naïve fish no protection was 
transferred (Velji et al., 1991). A third explanation for a lack of antibacterial activity in LPS-
immunised barramundi is that LPS is not a protective antigen of Vibrio harveyi. This theory 
would need to be based on the assumption that the bacteriostatic assay does in fact give an 
indication to the protective nature of the bacterin in the absence of vaccination/challenge 
data. 
In other animals the protective role of LPS is controversial with conflicting results from 
passive and active immunisation experiments (Muniandy et al., 1998). In fish results are 
also variable, Baba et al. (1988) found better protection in carp from A. hydrophila infection 
with a crude preparation of LPS than with a bacterin. These authors suggested the lack of 
bacteria-agglutinating antibody indicated that protection was not due to humoral immunity. 
The dominant antigen in Gram negative bacterial vaccines is LPS in that the majority of 
antibody is directed against the 0-antigens (i.e. the repeating oligosaccharide units) 
(Morrison and Ryan, 1979). However, it should be noted that oligosaccharide units of LPS 
are extremely heterogenous within species and strains (Morrison and Ryan, 1979) which 
may impact on the protective nature of LPS as an antigen. Using a V. anguillarum and 
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rainbow trout model, it has been suggested that there is a link between the length of these 
units and the bactericidal activity of fish sera (Boesen et al., 1999b). These authors found a 
decrease in the high molecular weight (HMW) components of V. anguillarum 0-antigen 
when glucose was added to the culture medium and further that this decrease corresponded 
with an increase in susceptibility to killing by serum. It was postulated that existence of 
HMW 0-antigens on V. anguillarum cells may sterically hinder complement access to the 
cytoplasmic membrane (Boesen et al., 1999b). Analysis of LPS from V harveyi via SDS-
PAGE (Figure 6.1) showed a distinct lack of banding in the I-LMW region of the gel 
indicating the lack of an extensive range of 0-antigens. Based on the logic of Boesen et al. 
(1999b) this may indicate a susceptibility of V. harveyi to action by serum which agrees with 
my findings of V. harveyi inhibitory activity of IP-immunised barramundi sera. Expression 
of 0-antigen seems to be dependent on culture conditions (Boesen et al., 1999) and in 
laboratory cultures may be governed by mutations (Reeve, 1995). The implications of these 
findings for V. harveyi culture and vaccine development is not known, more work is 
required to test if these observations are applicable to environmental V. harveyi . 
The fact that LPS is the protective antigen for some fish pathogens poses an interesting 
question: how does it confer protection over time given that it is a classical T-independent 
antigen and therefore elicits a poor memory response? Retention of LPS within lymphoid 
tissue in salmonids has been shown to occur for up to 16 weeks (Press et al., 1996), and this 
persistence would enable constant exposure to B cells and subsequent antibody production. 
The concept of LPS inducing poor immunological memory seems challenged by 
observations in mice that a sub-immunogenic priming dose of LPS can lead to either 
immunological memory or unresponsiveness, depending on the serotype, although the 
mechanisms involved are not known (Elkins et al., 1989). Further in catfish, LPS was shown 
to act as a mitogen in sIg" lymphocytes (T cells) (Sizemore et al., 1984). Clearly, more work 
is required to fully elucidate the complexities involved in the interaction of LPS and the 
immune system. Although from a practical perspective the fact that bacterial vaccines, 
where LPS is the protective antigen, provide protection would indicate that the memory 
component has been elicited. 
140 
Another aspect of the of data presented in this thesis was the development of reagents to 
monitor specific humoral immunity in barramundi. These reagents have been used in 
experiments that investigated the adjuvant effect of recombinant interleukin 1B in 
barramundi (Bridle, 2000). A further application could be a more detailed examination of B 
cells and their expression given that some of the reagents seem capable of detecting B cells 
from populations of leucocytes. This apparent ability to bind B cells is fortuitous as 
mammalian polyclonal antibodies raised against Ig from fish are generally found to be 
reactive with all the fish lymphocytes (Miller et al., 1998). 
In conclusion, the work described in this thesis will contribute to the development of an 
efficacious vaccine against vibriosis caused by V. harveyi infection. The work also forms 
part of the growing body of information on barramundi immunity which will also be 
applicable in the development of vaccines against other pathogens. The results indicate the 
direction that further research should take, both to fully elucidate barramundi immunity and 
develop immunoprophylaxis. Evaluation of the bacterin by vaccination/challenge trials is 
still a priority. The phenomenon of immunological memory remains controversial for 
barramundi as it does for other teleosts. Although there are indications of memory induction 
after IP immunisation with a bacterin in barramundi immunological memory should 
continue to be an on-going area of research. Similarly, the protective role of LPS of V. 
harveyi is unclear and in vitro and in vivo growth conditions influencing expression of 0- 
antigens need definition. Full elucidation of mucosal immunity should enhance the prospects 
of success in delivery of vaccines by methods other than injection. Elicitation of systemic 
antibody after bacterin administration by immersion and anal intubation indicates that these 
two immunisation methods are worth pursuing. 
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